Antiviral Drugs That Are Approved or Under Evaluation for the Treatment of COVID-19

Last Updated: July 8, 2021

Summary Recommendations

Remdesivir is the only Food and Drug Administration-approved drug for the treatment of COVID-19. In this section, the COVID-19 Treatment Guidelines Panel (the Panel) provides recommendations for using antiviral drugs to treat COVID-19 based on the available data. As in the management of any disease, treatment decisions ultimately reside with the patient and their health care provider. For more information on these antiviral agents, see Table 2e.

Remdesivir

- See Therapeutic Management of Hospitalized Adults with COVID-19 for recommendations on using remdesivir with or without dexamethasone.

Ivermectin

- There is insufficient evidence for the Panel to recommend either for or against the use of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin in the treatment of COVID-19.

Nitazoxanide

- The Panel recommends against the use of nitazoxanide for the treatment of COVID-19, except in a clinical trial (BIIa).

Hydroxychloroquine or Chloroquine and/or Azithromycin

- The Panel recommends against the use of chloroquine or hydroxychloroquine and/or azithromycin for the treatment of COVID-19 in hospitalized patients (AI) and in nonhospitalized patients (AIIa).

Lopinavir/Ritonavir and Other HIV Protease Inhibitors

- The Panel recommends against the use of lopinavir/ritonavir and other HIV protease inhibitors for the treatment of COVID-19 in hospitalized patients (AI) and in nonhospitalized patients (AIII).

Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = One or more randomized trials without major limitations; IIA = Other randomized trials or subgroup analyses of randomized trials; IIb = Nonrandomized trials or observational cohort studies; III = Expert opinion

Antiviral Therapy

Because SARS-CoV-2 replication leads to many of the clinical manifestations of COVID-19, antiviral therapies are being investigated for the treatment of COVID-19. These drugs inhibit viral entry (via the angiotensin-converting enzyme 2 [ACE2] receptor and transmembrane serine protease 2 [TMPRSS2]), viral membrane fusion and endocytosis, or the activity of the SARS-CoV-2 3-chymotrypsin-like protease (3CLpro) and the RNA-dependent RNA polymerase. Because viral replication may be particularly active early in the course of COVID-19, antiviral therapy may have the greatest impact before the illness progresses to the hyperinflammatory state that can characterize the later stages of disease, including critical illness. For this reason, it is necessary to understand the role of antiviral medications in treating mild, moderate, severe, and critical illness in order to optimize treatment for people with COVID-19.

The following sections describe the underlying rationale for using different antiviral medications, provide the COVID-19 Treatment Guidelines Panel’s recommendations for using these medications to treat COVID-19, and summarize the existing clinical trial data. Additional antiviral therapies will be added to this section of the Guidelines as new evidence emerges.
References


Remdesivir

Last Updated: April 21, 2021

Remdesivir is an intravenous nucleotide prodrug of an adenosine analog. Remdesivir binds to the viral RNA-dependent RNA polymerase and inhibits viral replication through premature termination of RNA transcription. It has demonstrated in vitro activity against SARS-CoV-2. In a rhesus macaque model of SARS-CoV-2 infection, remdesivir treatment was initiated soon after inoculation; the remdesivir-treated animals had lower virus levels in the lungs and less lung damage than the control animals.

Remdesivir is approved by the Food and Drug Administration (FDA) for the treatment of COVID-19 in hospitalized adult and pediatric patients (aged ≥12 years and weighing ≥40 kg). It is also available through an FDA Emergency Use Authorization (EUA) for the treatment of COVID-19 in hospitalized pediatric patients weighing 3.5 kg to <40 kg or aged <12 years and weighing ≥3.5 kg. Remdesivir should be administered in a hospital or a health care setting that can provide a similar level of care to an inpatient hospital.

Remdesivir has been studied in several clinical trials for the treatment of COVID-19. The recommendations from the COVID-19 Treatment Guidelines Panel (the Panel) are based on the results of these studies. See Table 2a for more information.

The safety and efficacy of combination therapy of remdesivir with corticosteroids have not been rigorously studied in clinical trials; however, there are theoretical reasons that combination therapy may be beneficial in some patients with severe COVID-19. For the Panel’s recommendations on using remdesivir with or without dexamethasone in certain hospitalized patients, see Therapeutic Management of Hospitalized Adults With COVID-19.

Monitoring and Adverse Effects

Remdesivir can cause gastrointestinal symptoms (e.g., nausea), elevated transaminase levels, an increase in prothrombin time (without a change in the international normalized ratio), and hypersensitivity reactions.

Liver function tests and prothrombin time should be obtained in all patients before remdesivir is administered and during treatment as clinically indicated. Remdesivir may need to be discontinued if alanine transaminase (ALT) levels increase to >10 times the upper limit of normal and should be discontinued if an increase in ALT level and signs or symptoms of liver inflammation are observed.

Considerations in Patients With Renal Insufficiency

Each 100 mg vial of remdesivir lyophilized powder contains 3 g of sulfobutylether beta-cyclodextrin sodium (SBECD), whereas each 100 mg/20 mL vial of remdesivir solution contains 6 g of SBECD. SBECD is a vehicle that is primarily eliminated through the kidneys. A patient with COVID-19 who receives a loading dose of remdesivir 200 mg would receive 6 g to 12 g of SBECD, depending on the formulation. This amount of SBECD is within the safety threshold for patients with normal renal function. Accumulation of SBECD in patients with renal impairment may result in liver and renal toxicities. Clinicians may consider preferentially using the lyophilized powder formulation (which contains less SBECD) in patients with renal impairment.

Because both remdesivir formulations contain SBECD, patients with an estimated glomerular filtration rate (eGFR) of <50 mL/min were excluded from some clinical trials of remdesivir; other trials had an eGFR cutoff of <30 mL/min. Remdesivir is not recommended for patients with an eGFR <30 mL/
min due to lack of data. Renal function should be monitored before and during remdesivir treatment as clinically indicated.

In two observational studies that evaluated the use of remdesivir in hospitalized patients with COVID-19, no significant differences were reported in the incidences of adverse effects or acute kidney injury between patients with an estimated creatinine clearance (CrCl) <30 mL/min and those with an estimated CrCl ≥30 mL/min. One of these studies evaluated patients who primarily received the solution formulation of remdesivir (20 patients had an estimated CrCl <30 mL/min and 115 had an estimated CrCl ≥30 mL/min); the other study evaluated patients who received the lyophilized powder formulation (40 patients had an estimated CrCl <30 mL/min and 307 had an estimated CrCl ≥30 mL/min).

**Drug-Drug Interactions**

Clinical drug-drug interaction studies of remdesivir have not been conducted. In vitro, remdesivir is a substrate of cytochrome P450 (CYP) 3A4 and of the drug transporters organic anion-transporting polypeptide (OATP) 1B1 and P-glycoprotein. It is also an inhibitor of CYP3A4, OATP1B1, OATP1B3, and multidrug and toxin extrusion protein 1 (MATE1).

Minimal to no reduction in remdesivir exposure is expected when remdesivir is coadministered with dexamethasone, according to information provided by Gilead Sciences (written communication, July 2020). Chloroquine or hydroxychloroquine may decrease the antiviral activity of remdesivir; coadministration of these drugs is not recommended. Remdesivir is not expected to have any significant interactions with oseltamivir or baloxavir, according to information provided by Gilead Sciences (written communications, August and September 2020).

See Table 2e for more information.

**Considerations in Pregnancy**

- Pregnant patients were excluded from the clinical trials that evaluated the safety and efficacy of remdesivir for the treatment of COVID-19, but preliminary reports of remdesivir use in pregnant patients from the remdesivir compassionate use program are reassuring.
- Among 86 pregnant and postpartum hospitalized patients with severe COVID-19 who received compassionate use remdesivir, the therapy was well tolerated, with a low rate of serious adverse events.
- Remdesivir should not be withheld from pregnant patients if it is otherwise indicated.

**Considerations in Children**

- The safety and effectiveness of using remdesivir to treat COVID-19 have not been evaluated in pediatric patients aged <12 years or weighing <40 kg.
- Remdesivir is available through an FDA EUA for the treatment of COVID-19 in hospitalized pediatric patients weighing 3.5 kg to <40 kg or aged <12 years and weighing ≥3.5 kg.
- A clinical trial is currently evaluating the pharmacokinetics of remdesivir in children (ClinicalTrials.gov Identifier NCT04431453).

**Clinical Trials**

Several clinical trials that are evaluating the use of remdesivir for the treatment of COVID-19 are currently underway or in development. Please see ClinicalTrials.gov for the latest information.
References


## Table 2a. Remdesivir: Selected Clinical Data

*Last Updated: February 11, 2021*

The clinical trials described in this table do not represent all the trials that the Panel reviewed while developing the recommendations for RDV. The studies summarized below are those that have had the greatest impact on the Panel’s recommendations.

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Methods</th>
<th>Results</th>
<th>Limitations and Interpretation</th>
</tr>
</thead>
</table>
| Adaptive COVID-19 Treatment Trial (ACTT-1)^1 | Key Inclusion Criteria:  
- Aged ≥18 years  
- Laboratory-confirmed SARS-CoV-2 infection  
- At least 1 of the following conditions:  
  - Pulmonary infiltrates, as determined by radiographic imaging  
  - SpO₂ ≤94% on room air  
  - Required supplemental oxygen  
  - Required mechanical ventilation  
  - Required ECMO  

Key Exclusion Criteria:  
- ALT or AST >5 times ULN  
- eGFR <30 mL/min  
- Pregnancy or breastfeeding  

Interventions:  
- IV RDV 200 mg on Day 1, then 100 mg daily for up to 9 more days  
- Placebo for 10 days  

Primary Endpoint:  
- Time to clinical recovery  

Ordinal Scale Definitions:  
1. Not hospitalized, no limitations  
2. Not hospitalized, with limitations  
3. Hospitalized, no active medical problems  

Number of Participants:  
- RDV (n = 541) and placebo (n = 521)  

Participant Characteristics:  
- Median time from symptom onset to randomization was 9 days (IQR 6–12 days).  

Outcomes  
- **Overall Results:**  
  - RDV reduced time to recovery compared to placebo (10 days vs. 15 days; RRR 1.29; 95% CI, 1.12–1.49; *P* < 0.001).  
  - Clinical improvement based on ordinal scale was higher at Day 15 in RDV arm (OR 1.5; 95% CI, 1.2–1.9; *P* < 0.001).  
  - No statistically significant difference in mortality by Day 29 between RDV and placebo arms (HR 0.73; 95% CI, 0.52–1.03; *P* = 0.07).  
  - Benefit of RDV was greatest in patients randomized during the first 10 days after symptom onset.  

Results by Disease Severity at Enrollment:  
- No difference in median time to recovery between arms among patients who had mild to moderate disease at enrollment.  
- Benefit of RDV for reducing time to recovery was clearest in patients who required supplemental oxygenation at enrollment (n = 435; RRR 1.45; 95% CI, 1.18–1.79), and RDV appeared to confer  

Limitations:  
- Wide range of disease severity; study was not powered to detect differences within subgroups  
- Powered to detect differences in clinical improvement, not mortality  
- No data collected on longer-term morbidity  

Interpretation:  
- In patients with severe COVID-19, RDV reduced time to clinical recovery.  
- Benefit of RDV was most apparent in hospitalized patients on supplemental oxygen.  
- No observed benefit in those on high-flow oxygen, noninvasive ventilation, mechanical ventilation, or ECMO, but the study was not powered to detect differences within subgroups.  
- No observed benefit of RDV in patients with mild or moderate COVID-19, but the number of participants in these categories was relatively small.
### Adaptive COVID-19 Treatment Trial (ACTT-1)\(^1\), continued

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Methods</th>
<th>Results</th>
<th>Limitations and Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>4. Hospitalized, not on oxygen</td>
<td>a survival benefit in this subgroup (HR for death by Day 29 0.30; 95% CI, 0.14–0.64).</td>
<td>• No observed difference in time to recovery between arms in patients on high-flow oxygen or noninvasive ventilation at enrollment (RRR 1.09; 95% CI, 0.76–1.57). No evidence that RDV affected mortality rate in this subgroup (HR 1.02; 95% CI, 0.54–1.91).</td>
<td></td>
</tr>
<tr>
<td>5. Hospitalized, on oxygen</td>
<td></td>
<td>• No observed difference in time to recovery between arms in patients on mechanical ventilation or ECMO at enrollment (RRR 0.98; 95% CI, 0.70–1.36). No evidence that RDV affected mortality rate in this subgroup (HR 1.13; 95% CI, 0.67–1.89).</td>
<td></td>
</tr>
<tr>
<td>6. Hospitalized, on high-flow oxygen or noninvasive mechanical ventilation</td>
<td></td>
<td>Safety Results:</td>
<td></td>
</tr>
<tr>
<td>7. Hospitalized, on mechanical ventilation or ECMO</td>
<td></td>
<td>• Percentages of patients with SAEs were similar between arms (25% vs. 32%).</td>
<td></td>
</tr>
<tr>
<td>8. Death</td>
<td></td>
<td>• Transaminase elevations: 6% of RDV recipients, 10.7% of placebo recipients</td>
<td></td>
</tr>
</tbody>
</table>

### Remdesivir Versus Placebo for Severe COVID-19 in China\(^2\)

<table>
<thead>
<tr>
<th>Multicenter, placebo-controlled, double-blind RCT in hospitalized patients with severe COVID-19 (n = 237)</th>
<th>Key Inclusion Criteria:</th>
<th>Number of Participants:</th>
<th>Limitations:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multicenter, placebo-controlled, double-blind RCT in hospitalized patients with severe COVID-19 (n = 237)</td>
<td>• Aged ≥18 years</td>
<td>ITT analysis: RDV (n = 158) and placebo (n = 78)</td>
<td>• Sample size did not have sufficient power to detect differences in clinical outcomes.</td>
</tr>
<tr>
<td></td>
<td>• Laboratory-confirmed SARS-CoV-2 infection</td>
<td>Study stopped before reaching target enrollment of 453 patients due to control of the COVID-19 outbreak in China.</td>
<td>• Use of concomitant medications (i.e., corticosteroids, LPV/RTV, IFNs) may have obscured effects of RDV.</td>
</tr>
<tr>
<td></td>
<td>• Time from symptom onset to randomization &lt;12 days</td>
<td>Participant Characteristics:</td>
<td>Interpretation:</td>
</tr>
<tr>
<td></td>
<td>• SpO(_2) ≤94% on room air or PaO(_2)/FiO(_2) &lt;300 mm Hg</td>
<td>• Median time from symptom onset to randomization: 9 days for RDV arm, 10 days for placebo arm</td>
<td>• No difference in time to clinical improvement, 28-day mortality, or rate of SARS-CoV-2 clearance between RDV-treated and placebo-treated patients;</td>
</tr>
<tr>
<td></td>
<td>• Radiographically confirmed pneumonia</td>
<td>• Receipt of corticosteroids: 65% of patients in RDV arm, 68% in placebo arm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Key Exclusion Criteria:</td>
<td>• Receipt of LPV/RTV: 28% of patients in RDV arm, 29% in placebo arm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• ALT or AST &gt;5 times ULN</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• eGFR &lt;30 mL/min</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Pregnancy or breastfeeding</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Remdesivir Versus Placebo for Severe COVID-19 in China², continued

**Interventions:**
- IV RDV 200 mg on Day 1, then 100 mg daily for 9 days
- Saline placebo for 10 days

**Primary Endpoint:**
- Time to clinical improvement, defined as improvement on an ordinal scale or being discharged alive from the hospital

**Results:**
- Receipt of IFN alfa-2b: 29% of patients in RDV arm, 38% in placebo arm

**Outcomes:**
- No difference in time to clinical improvement between RDV and placebo arms (median time 21 days vs. 23 days; HR 1.23; 95% CI, 0.87–1.75).
- For patients who started RDV or placebo within 10 days of symptom onset, faster time to clinical improvement was seen with RDV (median time 18 days vs. 23 days; HR 1.52; 95% CI, 0.95–2.43); however, this was not statistically significant.
- 28-day mortality was similar between arms (14% of patients in RDV arm, 13% in placebo arm).
- No difference between arms in SARS-CoV-2 viral load at baseline, and rate of decline over time was similar.
- Percentage of patients with AEs: 66% in RDV arm, 64% in placebo arm
- Discontinuations due to AEs: 12% of patients in RDV arm, 5% in placebo arm

**Limitations and Interpretation:**
- However, study was underpowered to detect differences in these outcomes between arms.

### World Health Organization Solidarity Trial³

**International, open-label, adaptive RCT with multiple treatment arms that enrolled hospitalized patients with COVID-19 (n = 11,330). In 1 arm, patients received RDV.**

**Key Inclusion Criteria:**
- Aged ≥18 years
- Not known to have received any study drug
- Not expected to be transferred elsewhere within 72 hours
- Physician reported no contraindications to study drugs

**Interventions:**
- IV RDV 200 mg on Day 0, then 100 mg daily on Days 1–9
- Local SOC

**Number of Participants:**
- ITT analysis: RDV (n = 2,743) and SOC (n = 2,708)

**Participant Characteristics:**
- Percentage of patients aged 50–69 years: 47% in RDV arm, 48% in SOC arm
- Percentage of patients aged ≥70 years: 18% in RDV arm, 17% in SOC arm
- 67% of patients in both arms were on supplemental oxygen at entry.
- 9% of patients in both arms were mechanically ventilated at entry.

**Limitations:**
- Open-label study design limits the ability to assess time to recovery; clinicians and patients were aware of treatment assignment, so RDV may have been continued to complete the treatment course even if the patient had improved.
- No data on time from symptom onset to enrollment
- No assessment of outcomes post hospital discharge
<table>
<thead>
<tr>
<th>Study Design</th>
<th>Methods</th>
<th>Results</th>
<th>Limitations and Interpretation</th>
</tr>
</thead>
</table>
| World Health Organization Solidarity Trial, continued | Primary Endpoint:  
- In-hospital mortality  
Secondary Endpoints:  
- Initiation of mechanical ventilation  
- Duration of hospitalization | Percentage of patients hospitalized for ≥2 days at entry: 40% in RDV arm, 39% in SOC arm  
Percentages of patients with comorbid conditions were similar between RDV and SOC arms: diabetes (26% and 25%), heart disease (21% both groups), and chronic lung disease (6% and 5%).  
48% of patients in both arms received corticosteroids. | RDV did not decrease in-hospital mortality in hospitalized patients when compared to local SOC. |
| Remdesivir Versus Standard of Care in Hospitalized Patients with Moderate COVID-19 | Open-label randomized trial in hospitalized patients (n = 596) | Key Inclusion Criteria:  
- Laboratory-confirmed SARS-CoV-2 infection  
- Moderate pneumonia, defined as radiographic evidence of pulmonary infiltrates and SpO₂ >94% on room air  
Key Exclusion Criteria:  
- ALT or AST >5 times ULN  
- CrCl <50 mL/min | Number of Participants:  
- 584 patients began treatment: 10-day RDV (n = 193), 5-day RDV (n = 191), and SOC (n = 200)  
Participant Characteristics:  
- Demographic and baseline disease characteristics were similar across all arms.  
Outcomes:  
- 5-day RDV had significantly higher odds of better clinical status distribution on Day 11 than SOC (OR 1.65; 95% CI, 1.09–2.48; P = 0.02). | Limitations:  
- Open-label design may have affected decisions related to concomitant medication use and hospital discharge.  
- Greater proportion of patients in SOC arm received HCQ, LPV/RTV, or AZM, which may cause AEs and have not shown clinical benefits in hospitalized patients with COVID-19. |
## Remdesivir Versus Standard of Care in Hospitalized Patients with Moderate COVID-19

### Interventions:
- IV RDV 200 mg on Day 1, then 100 mg daily for 9 days
- IV RDV 200 mg on Day 1, then 100 mg daily for 4 days
- Local SOC

### Primary Endpoint:
- Clinical status on Day 11, as measured by a 7-point ordinal scale

### Results
- Clinical status distribution on Day 11 was not significantly different between the 10-day RDV and SOC arms ($P = 0.18$).
- By Day 28, there were more hospital discharges among patients who received RDV (89% in 5-day arm and 90% in 10-day arm) than those who received SOC (83%).
- Mortality was low in all arms (1% to 2%).
- Percentages of patients with AEs in RDV arms vs. SOC arm: nausea (10% vs. 3%), hypokalemia (6% vs. 2%), and headache (5% vs. 3%)

### Limitations and Interpretation
- No data on time to return to activity for discharged patients

### Interpretation:
- Hospitalized patients with moderate COVID-19 who received 5 days of RDV had better outcomes than those who received SOC; however, difference between arms was of uncertain clinical importance.

## Different Durations of Remdesivir Treatment in Hospitalized Patients

### Manufacturer-sponsored, multinational, randomized, open-label trial in hospitalized patients with COVID-19 (n = 402)

### Key Inclusion Criteria:
- Aged ≥12 years
- Laboratory-confirmed SARS-CoV-2 infection
- Radiographic evidence of pulmonary infiltrates
- $\text{SpO}_2 \leq 94\%$ on room air or receipt of supplemental oxygen

### Key Exclusion Criteria:
- Receipt of mechanical ventilation or ECMO
- Multiorgan failure
- ALT or AST >5 times ULN
- Estimated CrCl <50 mL/min

### Interventions:
- IV RDV 200 mg on Day 1, then 100 mg daily for 4 days
- IV RDV 200 mg on Day 1, then 100 mg daily for 9 days

### Primary Endpoint:
- Clinical status at Day 14, as measured by a 7-point ordinal scale

### Number of Participants:
- 397 participants began treatment: 5-day RDV (n = 200) and 10-day RDV (n = 197)

### Participant Characteristics:
- At baseline, patients in 10-day arm had worse clinical status (based on ordinal scale distribution) than those in 5-day arm ($P = 0.02$)

### Outcomes:
- After adjusting for imbalances in baseline clinical status, Day 14 distribution in clinical status on the ordinal scale was similar between arms ($P = 0.14$).
- Time to achieve clinical improvement of at least 2 levels on the ordinal scale (median day of 50% cumulative incidence) was similar between arms (10 days vs. 11 days).
- Median durations of hospitalization among patients discharged on or before Day 14 were similar between 5-day (7 days; IQR 6–10 days) and 10-day arms (8 days; IQR 5–10 days).
- Percentages of patients with SAEs: 35% in 10-day arm, 21% in 5-day arm

### Limitations:
- This was an open-label trial without a placebo control arm, so clinical benefit of RDV (compared with no RDV) could not be assessed.
- There were baseline imbalances in clinical status of patients in the 5-day and 10-day arms.

### Interpretation:
- In hospitalized patients with severe COVID-19 who were not on mechanical ventilation or ECMO, RDV treatment for 5 or 10 days had a similar clinical benefit.
Key: AE = adverse effects; ALT = alanine transaminase; AST = aspartate aminotransferase; AZM = azithromycin; CrCl = creatinine clearance; ECMO = extracorporeal membrane oxygenation; eGFR = estimated glomerular filtration rate; HCQ = hydroxychloroquine; IFN = interferon; ITT = intention to treat; IV = intravenous; LPV/RTV = lopinavir/ritonavir; the Panel = the COVID-19 Treatment Guidelines Panel; PaO₂/FiO₂ = ratio of arterial partial pressure of oxygen to fraction of inspired oxygen; RCT = randomized controlled trial; RDV = remdesivir; RRR = recovery rate ratio; SAE = serious adverse effects; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; SOC = standard of care; SpO₂ = saturation of oxygen; ULN = upper limit of normal

References


Chloroquine or Hydroxychloroquine and/or Azithromycin

Last Updated: July 8, 2021

Chloroquine is an antimalarial drug that was developed in 1934. Hydroxychloroquine, an analogue of chloroquine, was developed in 1946. Hydroxychloroquine is used to treat autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis, in addition to malaria.

Both chloroquine and hydroxychloroquine increase the endosomal pH, which inhibits fusion between SARS-CoV-2 and the host cell membrane. Chloroquine inhibits glycosylation of the cellular angiotensin-converting enzyme 2 (ACE2) receptor, which may interfere with the binding of SARS-CoV to the cell receptor. In vitro studies have suggested that both chloroquine and hydroxychloroquine may block the transport of SARS-CoV-2 from early endosomes to endolysosomes, possibly preventing the release of the viral genome. Both chloroquine and hydroxychloroquine also have immunomodulatory effects, which have been hypothesized to be another potential mechanism of action for the treatment of COVID-19. Azithromycin has antiviral and anti-inflammatory properties. When used in combination with hydroxychloroquine, it has been shown to have a synergistic effect on SARS-CoV-2 in vitro and in molecular modeling studies. However, despite demonstrating antiviral activity in some in vitro systems, neither hydroxychloroquine plus azithromycin nor hydroxychloroquine alone reduced upper or lower respiratory tract viral loads or demonstrated clinical efficacy in a rhesus macaque model.

The safety and efficacy of chloroquine or hydroxychloroquine with or without azithromycin and azithromycin alone have been evaluated in randomized clinical trials, observational studies, and/or single-arm studies. Please see Table 2b for more information.

**Recommendation**

- The COVID-19 Treatment Guidelines Panel (the Panel) **recommends against** the use of chloroquine or hydroxychloroquine and/or azithromycin for the treatment of COVID-19 in hospitalized patients (AI) and in nonhospitalized patients (AIIa).

**Rationale**

**Hospitalized Patients**

In a large randomized controlled platform trial of hospitalized patients in the United Kingdom (RECOVERY), hydroxychloroquine did not decrease 28-day mortality when compared to the usual standard of care. Patients who were randomized to receive hydroxychloroquine had a longer median hospital stay than those who received the standard of care. In addition, among patients who were not on invasive mechanical ventilation at the time of randomization, those who received hydroxychloroquine were more likely to subsequently require intubation or die during hospitalization than those who received the standard of care.

The results from several additional large randomized controlled trials have been published; these trials have failed to show a benefit for hydroxychloroquine with or without azithromycin or azithromycin alone in hospitalized adults with COVID-19. In the Solidarity trial, an international randomized controlled platform trial that enrolled hospitalized patients with COVID-19, the hydroxychloroquine arm was halted for futility. There was no difference in in-hospital mortality between patients in the hydroxychloroquine arm and those in the control arm. Similarly, PETAL, a randomized, placebo-controlled, blinded study, was stopped early for futility. In this study, there was no difference in the median scores on the COVID Outcomes Scale between patients who received hydroxychloroquine and those who received placebo. Data from two additional randomized studies of hospitalized patients...
with COVID-19 did not support using hydroxychloroquine plus azithromycin over hydroxychloroquine alone.\textsuperscript{10,11} In RECOVERY, azithromycin alone (without hydroxychloroquine) did not improve survival or other clinical outcomes when compared to the usual standard of care.\textsuperscript{12}

In addition to these randomized trials, data from large retrospective observational studies do not consistently show evidence of a benefit for hydroxychloroquine with or without azithromycin in hospitalized patients with COVID-19.\textsuperscript{13-15} Please see Table 2b or the archived versions of the Guidelines for more information.

Given the lack of a benefit seen in the randomized clinical trials, the Panel \textbf{recommends against} using hydroxychloroquine or chloroquine and/or azithromycin to treat COVID-19 in hospitalized patients (A1).

**Nonhospitalized Patients**

Several randomized trials have not shown a clinical benefit for hydroxychloroquine in nonhospitalized patients with early, asymptomatic, or mild COVID-19.\textsuperscript{16,17} In an open-label trial, Mitja et al. randomized 307 nonhospitalized people who were recently confirmed to have COVID-19 to receive hydroxychloroquine or no antiviral treatment. Patients in the hydroxychloroquine arm received hydroxychloroquine 800 mg on Day 1 followed by 400 mg daily for an additional 6 days. The authors reported no difference in the mean reduction in SARS-CoV-2 RNA at Day 3 or the time to clinical improvement between the two arms (see Table 2b for more information). In another trial, treating patients who had asymptomatic or mild COVID-19 with hydroxychloroquine with or without azithromycin did not result in greater rates of virologic clearance (as measured by a negative polymerase chain reaction [PCR] result on Day 6).\textsuperscript{18}

An open-label, prospective, randomized trial compared oral azithromycin 500 mg once daily for 3 days plus standard of care to standard of care alone in nonhospitalized, high-risk, older adults who had laboratory-confirmed or suspected COVID-19. No differences were observed between the arms in the primary endpoints of time to first self-reported recovery and hospitalization or death due to COVID-19. These findings remained consistent in an analysis that was restricted to participants with positive SARS-CoV-2 PCR results. The study was ultimately halted due to futility.\textsuperscript{19} Similarly, in a preliminary report from ATOMIC-2, adding oral azithromycin 500 mg once daily to standard of care for 14 days did not reduce the risk of hospitalization or death among 292 participants with mild to moderate COVID-19.\textsuperscript{20}

While ongoing clinical trials are still evaluating the use of chloroquine, hydroxychloroquine, and azithromycin in outpatients, the existing data suggest that it is unlikely that clinical benefits will be identified for these agents. The Panel \textbf{recommends against} the use of chloroquine or hydroxychloroquine and/or azithromycin for the treatment of COVID-19 in nonhospitalized patients (AIIa).

**Adverse Effects**

Chloroquine and hydroxychloroquine have similar toxicity profiles, although hydroxychloroquine is better tolerated and has a lower incidence of toxicity than chloroquine. Cardiac adverse events that have been reported in people who received hydroxychloroquine include QTc prolongation, Torsades de Pointes, ventricular arrhythmia, and cardiac deaths.\textsuperscript{21}

The use of azithromycin has also been associated with QTc prolongation,\textsuperscript{22} and using it in combination with hydroxychloroquine has been associated with a higher incidence of QTc prolongation and cardiac adverse events in patients with COVID-19.\textsuperscript{23,24}

**Drug-Drug Interactions**

Chloroquine and hydroxychloroquine are moderate inhibitors of cytochrome P450 2D6, and these drugs...
are also P-glycoprotein inhibitors. Chloroquine and hydroxychloroquine may decrease the antiviral activity of remdesivir; coadministration of these drugs is not recommended.25

**Drug Availability**

Hydroxychloroquine, chloroquine, and azithromycin are not approved by the Food and Drug Administration (FDA) for the treatment of COVID-19. Furthermore, the FDA Emergency Use Authorization for hydroxychloroquine and chloroquine was revoked in June 2020.

**References**


### Table 2b. Chloroquine or Hydroxychloroquine and/or Azithromycin: Selected Clinical Data

*Last Updated: July 8, 2021*

The information in this table may include data from preprints or articles that have not been peer reviewed. This section will be updated as new information becomes available. Please see [ClinicalTrials.gov](https://clinicaltrials.gov) for more information on clinical trials that are evaluating CQ, HCQ, and/or AZM.

The Panel has reviewed other clinical studies of HCQ with or without AZM, CQ, and AZM for the treatment of COVID-19. These studies have limitations that make them less definitive and informative than the studies discussed here. The Panel’s summaries and interpretations of some of those studies are available in the archived versions of the COVID-19 Treatment Guidelines.

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Methods</th>
<th>Results</th>
<th>Limitations and Interpretation</th>
</tr>
</thead>
</table>
| **Solidarity Trial: Hydroxychloroquine in Hospitalized Patients With COVID-19**
  
Open-label randomized controlled platform trial with multiple arms; in 1 arm, hospitalized patients received HCQ (*n* = 11,330) | **Key Inclusion Criteria:**
- Aged ≥18 years
- Received a diagnosis of COVID-19  
**Key Exclusion Criteria:**
- Already receiving study drug
- Expected to be transferred elsewhere within 72 hours
  
**Interventions:**
- HCQ plus local SOC. Patients received a loading dose of HCQ 800 mg PO at entry, then HCQ 800 mg PO 6 hours later followed by a daily dose of HCQ 400 mg PO twice daily for 10 days, starting 12 hours after the entry dose.
- Local SOC alone  
**Number of Participants:**
- ITT analysis: HCQ (*n* = 947) and HCQ control (*n* = 906)
- Enrollment occurred between March 22 and October 4, 2020.

**Participant Characteristics:**
- 35% of patients enrolled in each arm were aged <50 years; 21% of patients were aged ≥70 years.
- 21% to 23% of patients had diabetes mellitus, 20% to 21% had heart disease, and 6.5% to 7% had chronic lung disease.
- At entry, 36% to 38% of patients were not on supplemental oxygen, 53% to 55% were receiving supplemental oxygen only, and 9% were receiving IMV.
- SOC included corticosteroids for 23% of patients in HCQ arm and 22% of patients in SOC only arm.

**Outcomes:**
- No significant difference in in-hospital mortality; 104 patients (10.2%) in HCQ arm and 84 patients (8.9%) in SOC arm died by Day 28 (rate ratio 1.19; 95% CI, 0.89–1.59; *P* = 0.23).  
**Key Limitations:**
- Not blinded
- Disease severity varied widely among patients.

**Interpretation:**
- HCQ does not decrease in-hospital mortality in hospitalized patients with COVID-19 when compared to SOC.
- HCQ does not decrease the need for mechanical ventilation when compared to SOC.
- There was no evidence of harm in the HCQ arm.
### Solidarity Trial: Hydroxychloroquine in Hospitalized Patients With COVID-19

**Primary Endpoint:**
- In-hospital mortality (i.e., death during the original hospitalization; follow-up ended at discharge from the hospital)

**Results:**
- Subgroup analyses based on age or respiratory support at entry reported no significant difference in mortality between the arms.
- No difference between the arms in the secondary outcome of initiation of ventilation, and no difference in the composite outcome of in-hospital mortality or initiation of ventilation.
- The number of deaths due to any cardiac cause during the 14 days after enrollment (the dosing period) was lower in these 2 arms than in the other study arms (the RDV, LPV/RTV, and IFN arms and their respective control arms).

### PETAL Trial: Hydroxychloroquine in Hospitalized Patients With COVID-19

**Randomized, placebo-controlled, blinded trial in hospitalized adults (n = 479)**

**Key Inclusion Criteria:**
- Laboratory-confirmed SARS-CoV-2 infection
- Symptoms of respiratory illness for <10 days

**Key Exclusion Criteria:**
- More than 1 dose of HCQ or CQ during the previous 10 days
- Prolonged QTc interval (>500 ms)

**Interventions:**
- HCQ 400 mg PO twice daily for 2 doses, then HCQ 200 mg PO twice daily for 8 doses
- Matching placebo

**Primary Endpoint:**
- Clinical status 14 days after randomization, as measured by a 7-point ordinal scale (the COVID Outcomes Scale)

**Number of Participants:**
- Enrollment occurred between April 2 and June 19, 2020.
- HCQ (n = 242) and placebo (n = 237)
- Planned sample size was 510 participants, but study enrollment was halted early due to futility.

**Participant Characteristics:**
- Median age was 58 and 57 years in HCQ and placebo arms, respectively; 33% of patients were aged ≥65 years and 24% of patients were Black/African American.
- 33% to 36% of patients had diabetes mellitus, 6% to 12% had heart disease, and 7% to 9% had chronic lung disease.
- At randomization, 5.4% of patients in HCQ arm and 8% in placebo arm were receiving IMV or ECMO. In both arms, 11% to 12% of patients were receiving noninvasive ventilation or HFNC oxygen, 46% to 48% were receiving low-flow oxygen, and 35% were receiving no respiratory support.
- Among the patients who received concomitant medications, 22% received RDV, 19% received AZM, and 18% received corticosteroids. There was no difference in concomitant medication use between the arms.

**Key Limitations:**
- It is unclear how the primary outcome of this study (a median COVID Outcomes Scale score) translates to clinical practice.

**Interpretation:**
- HCQ does not improve patient scores on the COVID Outcomes Scale in hospitalized patients with laboratory-confirmed SARS-CoV-2 infection when compared to placebo.
- HCQ did not improve survival or time to discharge in these patients when compared to placebo.
<table>
<thead>
<tr>
<th>Study Design</th>
<th>Methods</th>
<th>Results</th>
<th>Limitations and Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PETAL Trial: Hydroxychloroquine in Hospitalized Patients With COVID-19</strong>&lt;sup&gt;21&lt;/sup&gt;, continued</td>
<td></td>
<td><strong>Outcomes:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Median COVID Outcomes Scale score was 6 in HCQ arm (IQR 4–7) and 6 in placebo arm (IQR 4–7; aOR 1.02; 95% CI, 0.73–1.42).</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• No difference between the arms in the secondary outcome of all-cause, all-location death at Day 14 and Day 28</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• No difference between the arms in the number of any of the following systematically collected safety events: cardiac arrest treated with CPR, symptomatic hypoglycemia, ventricular arrhythmia, or seizure</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Among patients who had QTc assessed, 5.9% in HCQ arm and 3.3% in placebo arm had a recorded QTc interval &gt;500 ms during the first 5 days of dosing.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>RECOVERY Trial</strong>&lt;sup&gt;22&lt;/sup&gt;</td>
<td><strong>Key Inclusion Criteria:</strong></td>
<td><strong>Number of Participants:</strong></td>
<td><strong>Key Limitations:</strong></td>
</tr>
<tr>
<td></td>
<td>• Clinically suspected or laboratory-confirmed SARS-CoV-2 infection</td>
<td>• HCQ (n = 1,561) and SOC (n = 3,155)</td>
<td>• Not blinded</td>
</tr>
<tr>
<td></td>
<td><strong>Key Exclusion Criteria:</strong></td>
<td>Study enrollment ended early after investigators and trial-steering committee concluded that the data showed no benefit for HCQ.</td>
<td>• Information on occurrence of new major cardiac arrhythmia was not collected throughout the trial.</td>
</tr>
<tr>
<td></td>
<td>• Patients with prolonged QTc intervals were excluded from HCQ arm.</td>
<td><strong>Participant Characteristics:</strong></td>
<td><strong>Interpretation:</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Interventions:</strong></td>
<td>• Mean age was 65 years in both arms; 41% of patients were aged ≥70 years.</td>
<td>• HCQ does not decrease 28-day all-cause mortality when compared to the usual SOC in hospitalized patients with clinically suspected or laboratory-confirmed SARS-CoV-2 infection.</td>
</tr>
<tr>
<td></td>
<td>• HCQ 800 mg at entry and at 6 hours, then HCQ 400 mg every 12 hours for 9 days or until discharge</td>
<td>• 90% of patients had laboratory-confirmed SARS-CoV-2 infection.</td>
<td>• Patients who received HCQ had a longer median length of hospital stay, and those who were not on IMV at the time of randomization were more likely to require intubation or die during hospitalization if they received HCQ.</td>
</tr>
<tr>
<td></td>
<td>• Usual SOC</td>
<td>• 57% of patients had ≥1 major comorbidity: 27% had diabetes mellitus, 26% had heart disease, and 22% had chronic lung disease.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Primary Endpoint:</strong></td>
<td>• At randomization, 17% of patients were receiving IMV or ECMO, 60% were receiving oxygen only (with or without noninvasive ventilation), and 24% were receiving neither.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• All-cause mortality at Day 28 after randomization</td>
<td>• Use of AZM or another macrolide during the follow-up period was similar in both arms, as was use of dexamethasone.</td>
<td></td>
</tr>
<tr>
<td>Study Design</td>
<td>Methods</td>
<td>Results</td>
<td>Limitations and Interpretation</td>
</tr>
<tr>
<td>--------------</td>
<td>---------</td>
<td>---------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>RECOVERY Trial, continued</td>
<td></td>
<td>Outcomes:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• No significant difference in 28-day mortality between the 2 arms; 421 patients (26.8%) in HCQ arm and 790 patients (27.0%) in SOC arm had died by Day 28 (rate ratio 1.09; 95% CI, 0.97–1.23; (P=0.15)).</td>
<td>• Not blinded</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• A similar 28-day mortality for HCQ patients was reported during the post hoc exploratory analysis that was restricted to the 4,266 participants (90.5%) who had a positive SARS-CoV-2 test result.</td>
<td>• Follow-up period was restricted to 15 days.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Patients in HCQ arm were less likely to survive hospitalization and had a longer median time to discharge than patients in SOC arm.</td>
<td>Interpretation:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Patients who received HCQ and who were not on IMV at baseline had an increased risk of requiring intubation and an increased risk of death.</td>
<td>• Neither HCQ alone nor HCQ plus AZM improved clinical outcomes at Day 15 after randomization among hospitalized patients.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• At the beginning of the study, the researchers did not record whether a patient developed a major cardiac arrhythmia after study enrollment; however, these data were later collected for 735 patients (47.1%) in HCQ arm and 1,421 patients (45.0%) in SOC arm.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• No differences between the arms in the frequency of supraventricular tachycardia, ventricular tachycardia or fibrillation, or instances of AV block that required intervention; 1 case of Torsades de Pointes was reported in HCQ arm.</td>
<td></td>
</tr>
</tbody>
</table>

**Hydroxychloroquine and Hydroxychloroquine Plus Azithromycin for Mild or Moderate COVID-19**

<table>
<thead>
<tr>
<th>Key Inclusion Criteria:</th>
<th>Number of Participants:</th>
<th>Key Limitations:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Aged (\geq) 18 years</td>
<td>mITT analysis included patients with laboratory-confirmed SARS-CoV-2 infection ((n = 504)).</td>
<td>• Not blinded</td>
</tr>
<tr>
<td>• Clinically suspected or laboratory-confirmed SARS-CoV-2 infection</td>
<td></td>
<td>• Follow-up period was restricted to 15 days.</td>
</tr>
<tr>
<td>• Mild or moderate COVID-19</td>
<td>Participant Characteristics:</td>
<td>Interpretation:</td>
</tr>
<tr>
<td>• Duration of symptoms (\leq) 14 days</td>
<td>• Mean age was 50 years.</td>
<td>• Neither HCQ alone nor HCQ plus AZM improved clinical outcomes at Day 15 after randomization among hospitalized patients.</td>
</tr>
</tbody>
</table>

**Key Inclusion Criteria:**
- Aged \(\geq\) 18 years
- Clinically suspected or laboratory-confirmed SARS-CoV-2 infection
- Mild or moderate COVID-19
- Duration of symptoms \(\leq\) 14 days
Hydroxychloroquine and Hydroxychloroquine Plus Azithromycin for Mild or Moderate COVID-19

Key Exclusion Criteria:
- Need for >4 L of supplemental oxygen or ≥40% FiO₂ by face mask
- History of ventricular tachycardia
- QT interval ≥480 ms

Interventions:
- HCQ 400 mg twice daily for 7 days plus SOC
- HCQ 400 mg twice daily plus AZM 500 mg daily for 7 days plus SOC
- SOC alone

Primary Endpoint:
- Clinical status at Day 15, as measured by a 7-point ordinal scale among the patients with confirmed SARS-CoV-2 infection

Ordinal Scale Definitions:
1. Not hospitalized, no limitations
2. Not hospitalized, with limitations
3. Hospitalized, not on oxygen
4. Hospitalized, on oxygen
5. Hospitalized, oxygen administered by HFNC or noninvasive ventilation
6. Hospitalized, on mechanical ventilation
7. Death

Results:
- At baseline, 58.2% of patients were Ordinal Level 3; 41.8% were Ordinal Level 4.
- Median time from symptom onset to randomization was 7 days.
- 23.3% to 23.9% of patients received oseltamivir.

Outcomes:
- No significant difference in the odds of worse clinical status at Day 15 between patients in HCQ arm (OR 1.21; 95% CI, 0.69–2.11; P = 1.00) and patients in HCQ plus AZM arm (OR 0.99; 95% CI, 0.57–1.73; P = 1.00)
- No significant differences in secondary outcomes of the 3 arms, including progression to mechanical ventilation during the first 15 days and mean number of days "alive and free of respiratory support"
- A greater proportion of patients in HCQ plus AZM arm (39.3%) and HCQ arm (33.7%) experienced AEs than those in SOC arm (22.6%).
- QT prolongation was more common in patients who received HCQ plus AZM or HCQ alone than in patients who received SOC alone, but fewer patients in SOC arm had serial electrocardiographic studies performed during the follow-up period.

Limitations and Interpretation

with mild or moderate COVID-19.
# Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Methods</th>
<th>Results</th>
<th>Limitations and Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomized, placebo-controlled trial in nonhospitalized adults (n = 491)</td>
<td>Key Inclusion Criteria:</td>
<td>Number of Participants:</td>
<td>Key Limitations:</td>
</tr>
<tr>
<td>• Symptoms that were compatible with COVID-19 and lasted ≤4 days</td>
<td>• Contributed to primary endpoint data: HCQ (n = 212) and placebo (n = 211)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Either laboratory-confirmed SARS-CoV-2 infection or high-risk exposure within the previous 14 days</td>
<td></td>
<td></td>
<td>• This study enrolled a highly heterogeneous population.</td>
</tr>
<tr>
<td>Key Exclusion Criteria:</td>
<td>Participant Characteristics:</td>
<td></td>
<td>• Only 227 of 423 participants (53.7%) were confirmed PCR-positive for SARS-CoV-2.</td>
</tr>
<tr>
<td>• Aged &lt;18 years</td>
<td>• 241 patients were exposed to people with COVID-19 through their position as health care workers (57%), 106 were exposed through household contacts (25%), and 76 had other types of exposure (18%).</td>
<td></td>
<td>• Changing the primary endpoint without a new power calculation makes it difficult to assess whether the study is powered to detect differences in outcomes between the study arms.</td>
</tr>
<tr>
<td>• Hospitalized</td>
<td>• Median age was 40 years.</td>
<td></td>
<td>• This study used surveys for screening, symptom assessment, and adherence reporting.</td>
</tr>
<tr>
<td>• Receipt of certain medications</td>
<td>• 56% of patients were women.</td>
<td></td>
<td>• Visual analogue scales are not commonly used, and their ability to assess acute viral respiratory infections in clinical trials has not been validated.</td>
</tr>
<tr>
<td>Interventions:</td>
<td>• Only 3% of patients were Black.</td>
<td></td>
<td>Interpretation:</td>
</tr>
<tr>
<td>• HCQ 800 mg once, then HCQ 600 mg in 6–8 hours, then HCQ 600 mg once daily for 4 days</td>
<td>• Very few patients had comorbidities: 11% had hypertension, 4% had diabetes, and 68% had no chronic medical conditions.</td>
<td></td>
<td>• The study has some limitations, and it did not find evidence that early administration of HCQ reduced symptom severity in patients with mild COVID-19.</td>
</tr>
<tr>
<td>• Placebo</td>
<td>• 56% of patients were enrolled on Day 1 of symptom onset.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary Endpoints:</td>
<td>• 341 participants (81%) had either a positive PCR result or a high-risk exposure to a PCR-positive contact.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Planned primary endpoint was ordinal outcome by Day 14 in 4 categories: not hospitalized, hospitalized, ICU stay, or death.</td>
<td>Outcomes:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Because event rates were lower than expected, a new primary endpoint was defined: change in overall symptom severity over 14 days, measured by a 10-point, self-reported, visual analogue scale</td>
<td>• Compared to the placebo recipients, HCQ recipients had a nonsignificant 12% difference in improvement in symptoms between baseline and Day 14 (-2.60 vs. -2.33 points; ( P = 0.117 )).</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Ongoing symptoms were reported by 24% of those in HCQ arm and 30% of those in the placebo arm at Day 14 (( P = 0.21 )).</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• No difference in the incidence of hospitalization between the arms (4 patients in the HCQ arm vs. 10 patients in placebo arm); 2 of 10 placebo participants were hospitalized for reasons that were unrelated to COVID-19</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• A higher percentage of patients in HCQ arm experienced AEs than patients in placebo arm (43% vs. 22%; ( P &lt; 0.001 )).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Hydroxychloroquine in Nonhospitalized Adults With Mild COVID-19

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Methods</th>
<th>Results</th>
<th>Limitations and Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Open-label RCT in nonhospitalized adults (n = 353)</td>
<td>Key Inclusion Criteria:</td>
<td>Number of Participants: ITT analysis: HCQ (n = 136) and control (n = 157)</td>
<td>Key Limitations:</td>
</tr>
<tr>
<td></td>
<td>• Laboratory-confirmed SARS-CoV-2 infection</td>
<td>60 patients were excluded from the ITT analysis due to negative baseline RT-PCR, missing RT-PCR at follow-up visits, or consent withdrawal.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• &lt;5 days of mild COVID-19 symptoms</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Key Exclusion Criteria:</td>
<td>Participant Characteristics:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Moderate to severe COVID-19</td>
<td>• Mean age was 41.6 years.</td>
<td>Open-label, non-placebo-controlled trial</td>
</tr>
<tr>
<td></td>
<td>• Severe liver or renal disease</td>
<td>• 67% of patients were woman.</td>
<td>Study design allowed for the possibility of dropouts in control arm and over-reporting of AEs in HCQ arm.</td>
</tr>
<tr>
<td></td>
<td>• History of cardiac arrhythmia</td>
<td>• Majority of patients were health care workers (87%).</td>
<td>The intervention changed during the study; the authors initially planned to include HCQ plus DRV/COBI.</td>
</tr>
<tr>
<td></td>
<td>• QT prolongation</td>
<td>• 53% of patients reported chronic health conditions.</td>
<td></td>
</tr>
<tr>
<td>Interventions:</td>
<td>Median time from symptom onset to enrollment was 3 days (IQR 2–4 days).</td>
<td>The majority of the participants were relatively young health care workers.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• HCQ 800 mg on Day 1, then HCQ 400 mg once daily for 6 days</td>
<td>Most common COVID-19 symptoms were fever, cough, and sudden olfactory loss.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• No antiviral treatment (control arm)</td>
<td>Outcomes:</td>
<td>Interpretation:</td>
</tr>
<tr>
<td>Primary Endpoint:</td>
<td>Reduction in SARS-CoV-2 viral load, assessed using NP swabs on Days 3 and 7</td>
<td>• No significant difference in viral load reduction between control arm and HCQ arm at Day 3</td>
<td>Early administration of HCQ to patients with mild COVID-19 did not result in improvement in virologic clearance, a lower risk of disease progression, or a reduced time to symptom improvement.</td>
</tr>
<tr>
<td>Secondary Endpoints:</td>
<td>Disease progression up to Day 28</td>
<td>(-1.41 vs. -1.41 log_{10} copies/mL; difference of 0.01; 95% CI, -0.28 to 0.29), or at Day 7 (-3.37 vs. -3.44 log_{10} copies/mL; difference of -0.07; 95% CI, -0.44 to 0.29).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Time to complete resolution of symptoms</td>
<td>No difference in the risk of hospitalization between control arm and HCQ arm (7.1% vs. 5.9%; risk ratio 0.75; 95% CI, 0.32–1.77)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>No difference in the median time from randomization to the resolution of COVID-19 symptoms between the 2 arms (12.0 days in control arm vs. 10.0 days in HCQ arm; P = 0.38)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>A higher percentage of participants in the HCQ arm than in the control arm experienced AEs during the 28-day follow-up period (72% vs. 9%). Most common AEs were GI disorders and “nervous system disorders.”</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>SAEs were reported in 12 patients in control arm and 8 patients in HCQ arm. SAEs that occurred among patients in HCQ arm were not deemed to be related to the drug.</td>
<td></td>
</tr>
<tr>
<td>Study Design</td>
<td>Methods</td>
<td>Results</td>
<td>Limitations and Interpretation</td>
</tr>
<tr>
<td>-------------</td>
<td>---------</td>
<td>---------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>Observational Study on Hydroxychloroquine With or Without Azithromycin[^26]</td>
<td><strong>Key Inclusion Criteria:</strong>&lt;br&gt;• Laboratory-confirmed SARS-CoV-2 infection&lt;br&gt;<strong>Interventions:</strong>&lt;br&gt;• HCQ plus AZM&lt;br&gt;• HCQ alone&lt;br&gt;• AZM alone&lt;br&gt;• Neither drug&lt;br&gt;<strong>Primary Endpoint:</strong>&lt;br&gt;• In-hospital mortality&lt;br&gt;<strong>Secondary Endpoint:</strong>&lt;br&gt;• Cardiac arrest and arrhythmia or QT prolongation on an ECG</td>
<td><strong>Number of Participants:</strong>&lt;br&gt;• HCQ plus AZM (n = 735), HCQ alone (n = 271), AZM alone (n = 211), and neither drug (n = 221)&lt;br&gt;<strong>Participant Characteristics:</strong>&lt;br&gt;• Patients in the treatment arms had more severe disease at baseline than those who received neither drug.&lt;br&gt;<strong>Outcomes:</strong>&lt;br&gt;• In adjusted analyses, patients who received 1 of the 3 treatment regimens did not show a decreased in-hospital mortality rate when compared with those who received neither drug.&lt;br&gt;• Patients who received HCQ plus AZM had a greater risk of cardiac arrest than patients who received neither drug (OR 2.13; 95% CI, 1.12–4.05).&lt;br&gt;<strong>Key Limitations:</strong>&lt;br&gt;• This study has the inherent limitations of an observational study, including residual confounding from confounding variables that were unrecognized and/or unavailable for analysis.&lt;br&gt;<strong>Interpretation:</strong>&lt;br&gt;• Despite the limitations discussed above, these findings suggest that although HCQ and AZM are not associated with an increased risk of in-hospital death, the combination of HCQ and AZM may be associated with an increased risk of cardiac arrest.</td>
<td></td>
</tr>
<tr>
<td>Observational Study of Hydroxychloroquine Versus No Hydroxychloroquine in New York City[^27]</td>
<td><strong>Key Inclusion Criteria:</strong>&lt;br&gt;• Laboratory-confirmed SARS-CoV-2 infection&lt;br&gt;<strong>Key Exclusion Criteria:</strong>&lt;br&gt;• Intubation, death, or transfer to another facility within 24 hours of arriving at the emergency department&lt;br&gt;<strong>Interventions:</strong>&lt;br&gt;• HCQ 600 mg twice daily on Day 1, then HCQ 400 mg once daily for 4 days&lt;br&gt;• No HCQ&lt;br&gt;<strong>Primary Endpoint:</strong>&lt;br&gt;• Time from study baseline (24 hours after patients arrived at the ED) to intubation or death</td>
<td><strong>Number of Participants:</strong>&lt;br&gt;• Received HCQ (n = 811) and did not receive HCQ (n = 565)&lt;br&gt;<strong>Participant Characteristics:</strong>&lt;br&gt;• HCQ recipients were more severely ill at baseline than those who did not receive HCQ.&lt;br&gt;<strong>Outcomes:</strong>&lt;br&gt;• Using propensity scores to adjust for major predictors of respiratory failure and inverse probability weighting, the study demonstrated that HCQ use was not associated with intubation or death (HR 1.04; 95% CI, 0.82–1.32).&lt;br&gt;• No association between concomitant use of AZM and the composite endpoint of intubation or death (HR 1.03; 95% CI, 0.81–1.31)&lt;br&gt;<strong>Key Limitations:</strong>&lt;br&gt;• This study has the inherent limitations of an observational study, including residual confounding from confounding variables that were unrecognized and/or unavailable for analysis.&lt;br&gt;<strong>Interpretation:</strong>&lt;br&gt;• The use of HCQ for treatment of COVID-19 was not associated with harm or benefit in a large observational study.</td>
<td></td>
</tr>
</tbody>
</table>
**Key**: AE = adverse event; AV = atrioventricular; AZM = azithromycin; CPR = cardiopulmonary resuscitation; CQ = chloroquine; DRV/COBI = darunavir/cobicistat; ECG = electrocardiogram; ECMO = extracorporeal membrane oxygenation; ED = emergency department; FiO$_2$ = fraction of inspired oxygen; GI = gastrointestinal; HCQ = hydroxychloroquine; HFNC = high-flow nasal cannula; ICU = intensive care unit; IFN = interferon; IMV = invasive mechanical ventilation; ITT = intention-to-treat; LPV/RTV = lopinavir/ritonavir; mITT = modified intention-to-treat; NP = nasopharyngeal; the Panel = the COVID-19 Treatment Guidelines Panel; PCR = polymerase chain reaction; PO = orally; RCT = randomized controlled trial; RDV = remdesivir; RT-PCR = reverse transcription polymerase chain reaction; SAE = serious adverse event; SOC = standard of care

**References**


Ivermectin is a Food and Drug Administration (FDA)-approved antiparasitic drug that is used to treat several neglected tropical diseases, including onchocerciasis, helminthiases, and scabies. It is also being evaluated for its potential to reduce the rate of malaria transmission by killing mosquitoes that feed on treated humans and livestock. For these indications, ivermectin has been widely used and is generally well tolerated. Ivermectin is not approved by the FDA for the treatment of any viral infection.

Proposed Mechanism of Action and Rationale for Use in Patients With COVID-19

Reports from in vitro studies suggest that ivermectin acts by inhibiting the host importin alpha/beta-1 nuclear transport proteins, which are part of a key intracellular transport process that viruses hijack to enhance infection by suppressing the host’s antiviral response. In addition, ivermectin docking may interfere with the attachment of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human cell membrane. Ivermectin is thought to be a host-directed agent, which may be the basis for its broad-spectrum activity in vitro against the viruses that cause dengue, Zika, HIV, and yellow fever. Despite this in vitro activity, no clinical trials have reported a clinical benefit for ivermectin in patients with these viruses. Some studies of ivermectin have also reported potential anti-inflammatory properties, which have been postulated to be beneficial in people with COVID-19.

Some observational cohorts and clinical trials have evaluated the use of ivermectin for the prevention and treatment of COVID-19. Data from some of these studies can be found in Table 2c.

Recommendation

- There is insufficient evidence for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the use of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin in the treatment of COVID-19.

Rationale

Ivermectin has been shown to inhibit the replication of SARS-CoV-2 in cell cultures. However, pharmacokinetic and pharmacodynamic studies suggest that achieving the plasma concentrations necessary for the antiviral efficacy detected in vitro would require administration of doses up to 100-fold higher than those approved for use in humans. Even though ivermectin appears to accumulate in the lung tissue, predicted systemic plasma and lung tissue concentrations are much lower than 2 µM, the half-maximal inhibitory concentration (IC$_{50}$) against SARS-CoV-2 in vitro. Subcutaneous administration of ivermectin 400 µg/kg had no effect on SARS-CoV-2 viral loads in hamsters. However, there was a reduction in olfactory deficit (measured using a food-finding test) and a reduction in the interleukin (IL)-6:IL-10 ratio in lung tissues.

Since the last revision of this section of the Guidelines, the results of several randomized trials and retrospective cohort studies of ivermectin use in patients with COVID-19 have been published in peer-reviewed journals or have been made available as manuscripts ahead of peer review. Some clinical studies showed no benefits or worsening of disease after ivermectin use, whereas others reported shorter time to resolution of disease manifestations that were attributed to COVID-19, greater reduction in inflammatory marker levels, shorter time to viral clearance, or lower mortality rates in patients who received ivermectin than in patients who received comparator drugs or placebo.
However, most of these studies had incomplete information and significant methodological limitations, which make it difficult to exclude common causes of bias. These limitations include:

- The sample size of most of the trials was small.
- Various doses and schedules of ivermectin were used.
- Some of the randomized controlled trials were open-label studies in which neither the participants nor the investigators were blinded to the treatment arms.
- Patients received various concomitant medications (e.g., doxycycline, hydroxychloroquine, azithromycin, zinc, corticosteroids) in addition to ivermectin or the comparator drug. This confounded the assessment of the efficacy or safety of ivermectin.
- The severity of COVID-19 in the study participants was not always well described.
- The study outcome measures were not always clearly defined.

Table 2c includes summaries of key studies. Because most of these studies have significant limitations, the Panel cannot draw definitive conclusions on the clinical efficacy of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide further guidance on the role of ivermectin in the treatment of COVID-19.

### Monitoring, Adverse Effects, and Drug-Drug Interactions

- Ivermectin is generally well tolerated. Adverse effects may include dizziness, pruritis, nausea, or diarrhea.
- Neurological adverse effects have been reported with the use of ivermectin for the treatment of onchocerciasis and other parasitic diseases, but it is not clear whether these adverse effects were caused by ivermectin or the underlying conditions.\(^{28}\)
- Ivermectin is a minor cytochrome P 3A4 substrate and a p-glycoprotein substrate.
- Ivermectin is generally given on an empty stomach with water; however, administering ivermectin with food increases its bioavailability.
- The FDA issued a warning in April 2020 that ivermectin intended for use in animals should not be used to treat COVID-19 in humans.
- Please see Table 2c for additional information.

### Considerations in Pregnancy

In animal studies, ivermectin was shown to be teratogenic when given in doses that were maternotoxic. These results raise concerns about administering ivermectin to people who are in the early stages of pregnancy (prior to 10 weeks gestation).\(^{29}\) A 2020 systematic review and meta-analysis reviewed the incidence of poor maternal and fetal outcomes after ivermectin was used for its antiparasitic properties during pregnancy. However, the study was unable to establish a causal relationship between ivermectin use and poor maternal or fetal outcomes due to the quality of evidence. There are numerous reports of inadvertent ivermectin use in early pregnancy without apparent adverse effects.\(^{30-32}\) Therefore, there is insufficient evidence to establish the safety of using ivermectin in pregnant people, especially those in the later stages of pregnancy.

One study reported that the ivermectin concentrations secreted in breastmilk after a single oral dose were relatively low. No studies have evaluated the ivermectin concentrations in breastmilk in patients who received multiple doses.
Considerations in Children

Ivermectin is used in children weighing >15 kg for the treatment of helminthic infections, pediculosis, and scabies. The safety of using ivermectin in children weighing <15 kg has not been well established. Ivermectin is generally well tolerated in children, with a side effect profile similar to the one seen in adults. Currently, there are no available pediatric data from clinical trials to inform the use of ivermectin for the treatment or prevention of COVID-19 in children.

Clinical Trials

Several clinical trials that are evaluating the use of ivermectin for the treatment of COVID-19 are currently underway or in development. Please see ClinicalTrials.gov for the latest information.

References


13. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the


28. Chandler RE. Serious neurological adverse events after ivermectin—do they occur beyond the indication of


The Panel has reviewed other clinical studies of IVM for the treatment of COVID-19. However, those studies have limitations that make them less definitive and informative than the studies discussed here. The studies summarized below are those that have had the greatest impact on the Panel’s recommendations.

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Methods</th>
<th>Results</th>
<th>Limitations and Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivermectin Versus Placebo for Treatment of Mild COVID-19&lt;sup&gt;17&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Randomized, double-blind, placebo-controlled trial in Cali, Colombia (n = 476) | Key Inclusion Criteria:  
• Positive SARS-CoV-2 PCR result or positive antigen test result  
• Symptoms began ≤7 days prior to randomization  
• Mild disease (defined as receiving outpatient or inpatient care, but not receiving HFNC oxygen or mechanical ventilation) | Number of Participants:  
• IVM (n = 200) and placebo (n = 198) in primary analysis | Key Limitations:  
• Relatively small sample size  
• Primary endpoint was modified during the trial due to lower than expected event rates.  
• The first 65 patients received a placebo that smelled and tasted different from IVM.  
• The study enrolled a younger, healthier demographic than those who typically experience more serious cases of COVID-19.  
• Study included 4 hospitalized patients (out of 398).  
• The IVM dose used in this study was higher than the dose that is usually administered (IVM 200 μg/kg per day). |
| | Key Exclusion Criteria:  
• Asymptomatic disease  
• Severe pneumonia  
• Receipt of IVM within previous 5 days  
• Hepatic dysfunction/abnormal liver function tests | Participant Characteristics:  
• Median age was 37 years; 4% of patients in IVM arm and 8% in placebo arm were aged ≥65 years.  
• 39% of patients in IVM arm and 45% in placebo arm were male.  
• 79% of patients had no known comorbidities; median BMI in both arms was 26.  
• Median time from symptom onset to randomization was 5 days (IQR 4–6 days).  
• 62% of patients in IVM arm and 55% in placebo arm were not hospitalized and had no limitations of activities at baseline (ordinal scale 1); 38% and 44% were not hospitalized but had some limitations on activities, or they were receiving oxygen at home, or both (ordinal scale 2).  
• 1% of patients in both arms were hospitalized at baseline. | |
| | Interventions:  
• Oral IVM 300 μg/kg per day in solution for 5 days, taken primarily on an empty stomach  
• Placebo | Primary Outcomes:  
• No difference in time to resolution of symptoms (median 10 days in IVM arm vs. 12 days in placebo arm; HR 1.07; 95% CI, 0.87–1.32; P = 0.53)  
• Symptoms resolved in 82% of patients in IVM arm and 79% in placebo arm by Day 21. | Interpretation:  
• A 5-day course of IVM did not improve time to resolution of symptoms in patients with mild COVID-19. |
| | Primary Endpoints:  
• Time from randomization to resolution of symptoms within | Other Outcomes:  
• No significant difference between arms in proportion of patients who showed clinical deterioration of ≥2 points on the ordinal scale (3.5% in IVM arm vs. 2.0% in placebo arm; absolute difference -1.5%; 95% CI, -4.8% to 1.7%) | |

<sup>17</sup> Last Updated: July 19, 2021
### Study Design

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Methods</th>
<th>Results</th>
<th>Limitations and Interpretation</th>
</tr>
</thead>
</table>
| **Ivermectin Versus Placebo for Treatment of Mild COVID-19**<sup>17</sup>, continued | the 21-day follow-up period. Resolution of symptoms was defined as the first day a patient reported a score of 0 (no clinical evidence of infection) on an 8-point ordinal scale. | • No significant difference between arms in the odds of improvement in ordinal scale score and the proportion of patients who sought medical care or required escalation in care.  
• 8% of patients in IVM arm and 3% in placebo arm discontinued treatment due to an AE. None of the reported SAEs were considered to be related to study interventions. | |

### Ivermectin Versus Ivermectin Plus Doxycycline Versus Placebo for Treatment of COVID-19<sup>18</sup>

| Randomized, double-blind, placebo-controlled trial of hospitalized adults in Dhaka, Bangladesh (n = 72) | **Key Inclusion Criteria:**  
• Aged 18–65 years  
• Laboratory-confirmed SARS-CoV-2 infection with fever, cough, or sore throat  
• Admitted to hospital within previous 7 days | **Number of Participants:**  
• IVM (n = 24; 2 withdrew), IVM plus DOX (n = 24; 1 withdrew), and placebo (n = 24; 1 withdrew) | **Key Limitations:**  
• Small sample size  
• Unclear whether both IVM and DOX placebos were used.  
• Excluded patients with chronic diseases.  
• Disease appears to have been mild in all patients; thus, the reason for hospitalization is unclear.  
• Absolute changes in inflammatory markers were not presented, but were reportedly significant.  
• PCR results are not a validated surrogate marker for clinical efficacy. |

| **Key Exclusion Criteria:**  
• Chronic cardiac, renal, or liver disease | **Participant Characteristics:**  
• Mean age was 42 years.  
• 54% of patients were female.  
• Mean time from symptom onset to assessment was 3.83 days.  
• No patients required supplemental oxygen. | **Primary Outcomes:**  
• Shorter mean time to virologic clearance with IVM than placebo (9.7 days vs. 12.7 days; \( P = 0.02 \)), but not with IVM plus DOX (11.5 days; \( P = 0.27 \)).  
• Rates of virologic clearance were greater in IVM arm at Day 7 (HR 4.1; 95% CI, 1.1–14.7; \( P = 0.03 \)) and at Day 14 (HR 2.7; 95% CI, 1.2–6.0; \( P = 0.02 \)) compared to placebo, but not in the IVM plus DOX arm (HR 2.3; 95% CI, 0.6–9.0; \( P = 0.22 \) and HR 1.7; 95% CI, 0.8–4.0; \( P = 0.19 \)).  
• No statistically significant difference in time to resolution of fever, cough, or sore throat between IVM and placebo arms (\( P = 0.35 \), \( P = 0.18 \), and \( P = 0.35 \), respectively) or IVM plus DOX and placebo arms (\( P = 0.09 \), \( P = 0.23 \), and \( P = 0.09 \), respectively). | **Interpretation:**  
• A 5-day course of IVM resulted in faster virologic clearance than placebo, but not a faster time to resolution of symptoms (fever, cough, and sore throat). |

| **Interventions:**  
• IVM 12 mg PO once daily for 5 days  
• Single dose of IVM 12 mg PO plus DOX 200 mg PO on Day 1, then DOX 100 mg every 12 hours for 4 days  
• Placebo | **Primary Endpoints:**  
• Time to virologic clearance, measured by obtaining an NP swab for SARS-CoV-2 PCR on Days 3, 7, and 14, then weekly until PCR result was negative  
• Resolution of fever and cough within 7 days |  | |

---

*COVID-19 Treatment Guidelines*

Downloaded from [https://www.covid19treatmentguidelines.nih.gov/](https://www.covid19treatmentguidelines.nih.gov/) on 10/14/2021
Study Design | Methods | Results | Limitations and Interpretation
--- | --- | --- | ---
Ivermectin Versus Ivermectin Plus Doxycycline Versus Placebo for Treatment of COVID-19\textsuperscript{18}, continued | Other Outcomes:  
- Mean values of CRP, LDH, procalcitonin, and ferritin declined in all arms from baseline to Day 7, but there were no between-arm comparisons of the changes.  
- No between-arm differences in duration of hospitalization ($P = 0.93$).  
- No SAEs recorded.  | Because time to virologic clearance is not a validated surrogate marker for clinical efficacy, the clinical efficacy of IVM is unknown. |

Effectiveness and Safety of Adding Ivermectin to Treatment in Patients With Severe COVID-19\textsuperscript{19}

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Key Inclusion Criteria:</th>
<th>Number of Participants:</th>
<th>Key Limitations:</th>
</tr>
</thead>
</table>
| Randomized, single-blind trial of hospitalized adults in Turkey ($n = 66$) | - Hospitalized with PCR-confirmed SARS-CoV-2 infection  
- $\geq 1$ of the following severity criteria:  
  - Tachypnea ($\geq 30$ breaths/min), $\text{SpO}_2 <90\%$ on RA, or $\text{PaO}_2/\text{FiO}_2 <300$ mm Hg in patients who were receiving oxygen  
  - Presence of “specific” radiologic findings  
  - Mechanical ventilation  
  - Acute organ dysfunction | - IVM ($n = 36$) and SOC ($n = 30$)  
- 6 participants in IVM arm were excluded after genotyping. | - Small sample size  
- Time from symptom onset to intervention was not reported.  
- Study used nonstandard severity classification for COVID-19.  
- Primary endpoint was difficult to characterize; it was presented in the Methods section as a composite endpoint, but each component was analyzed separately.  
- Power analysis performed for virologic endpoint, not primary endpoint.  
- Only 57% of patients in IVM arm and 27% in SOC arm were evaluated for VL changes. |

| Key Exclusion Criteria: | Participant Characteristics: | Secondary Outcomes  
*Between-Arm Comparisons at Day 10:* | Interpretation: |
|---|---|---|---|
| - Aged $<18$ years  
- Pregnant or breast feeding  
- Autoimmune disease  
- Chronic liver or kidney disease  
- Immunosuppression  
- SNP mutation in MDR1/ABCB1 gene and/or haplotypes and mutations of the CYP3A4 gene (affects IVM metabolism and toxicity) | - Mean age was 58 years in IVM arm and 66 years in SOC arm.  
- 70% of patients were male in IVM arm and 63% were male in SOC arm.  
- Comorbidities (IVM vs. SOC): DM (30% vs. 33%), HTN (50% vs. 40%), CAD (17% vs. 27%) | - Clinical improvement at Day 5: 14 of 30 patients (46.7%) in IVM arm, 11 of 30 (36.7%) in SOC arm ($P = 0.43$)  
- Clinical improvement: 73.3% in IVM arm, 53.3% in SOC arm ($P = 0.10$)  
- IVM vs. SOC arm SOFA score at Day 10: $P = 0.50$  
- Mean $\text{SpO}_2$: 95.4% in IVM arm, 93.0% in SOC arm ($P = 0.032$)  
- Mean $\text{PaO}_2/\text{FiO}_2$: 236.3 mm Hg in IVM arm, 220.8 mm Hg in SOC arm ($P = 0.39$)  
- Serum CRP, ferritin, and D-dimer levels were lower in IVM arm than in SOC arm ($P = 0.02$, $P = 0.005$, and $P = 0.03$, respectively). | - A 5-day course of IVM in hospitalized patients with severe COVID-19 did not result in clinical improvement at the end of treatment, and no reduction in mortality was observed. |
<table>
<thead>
<tr>
<th>Study Design</th>
<th>Methods</th>
<th>Results</th>
<th>Limitations and Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Effectiveness and Safety of Adding Ivermectin to Treatment in Patients With Severe COVID-19</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Interventions:</strong></td>
<td>• IVM 200 μg/kg per day for 5 days plus SOC (HCQ plus favipiravir plus AZM)</td>
<td>• Change in SOFA score to Day 10: $P = 0.009$ in IVM arm, $P = 0.88$ in SOC arm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• SOC alone</td>
<td>• Mean changes in $SpO_2$, to Day 5: 89.9% to 93.5% ($P = 0.005$) in IVM arm, 89.7% to 93.0% ($P = 0.003$) in SOC arm</td>
<td>• Faster improvement of oxygenation and more pronounced reduction in inflammatory markers were observed in IVM arm.</td>
</tr>
<tr>
<td><strong>Primary Endpoint:</strong></td>
<td>“Clinical response” at Day 5: extubation (in mechanically ventilated patients), respiratory rate &lt;26 breaths/min, $SpO_2 &gt;90%$ on RA, $PaO_2/FiO_2 &gt;300$ mm Hg (if patient was receiving oxygen), presence of ≥2 of the 2-point reduction criteria in SOFA</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Key Secondary Endpoints:</strong></td>
<td>• Clinical response at Day 10: respiratory rate 22 to 24 breaths/min, $SpO_2 &gt;95%$ on RA, absence of oxygen requirement, and no need for intensive care</td>
<td>• 6 patients (20%) in IVM arm and 9 (30%) in SOC arm ($P = 0.37$).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Changes in $SpO_2$, $PaO_2/FiO_2$, and levels of CRP, ferritin, and D-dimer</td>
<td>• Average length of follow-up was 3 months.</td>
<td></td>
</tr>
<tr>
<td><strong>Chloroquine, Hydroxychloroquine, or Ivermectin in Patients With Severe COVID-19</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Randomized, double-blind, Phase 2 trial of hospitalized adults in Brazil (n = 168)</strong></td>
<td><strong>Key Inclusion Criteria:</strong></td>
<td><strong>Number of Participants:</strong></td>
<td><strong>Key Limitations:</strong></td>
</tr>
<tr>
<td></td>
<td>• Hospitalized with laboratory-confirmed SARS-CoV-2 infection (PCR or IgM positive)</td>
<td>• CQ (n = 61), HCQ (n = 54), and IVM (n = 53)</td>
<td>• Small sample size</td>
</tr>
<tr>
<td></td>
<td>• ≥1 of the following severity criteria:</td>
<td><strong>Participant Characteristics:</strong></td>
<td>• No placebo control</td>
</tr>
<tr>
<td></td>
<td>• Dyspnea</td>
<td>• Mean age was 53.4±15.6 years.</td>
<td>• No clear primary endpoint</td>
</tr>
<tr>
<td></td>
<td>• Tachypnea (&gt;30 breaths/min)</td>
<td>• 58.2% of patients were male.</td>
<td>Interpretation:</td>
</tr>
<tr>
<td></td>
<td>• $SpO_2 &lt;93%$</td>
<td>• 78.9% of patients were Hispanic.</td>
<td>• Use of IVM did not reduce risk of oxygen requirement, ICU admission, invasive mechanical ventilation, or death in</td>
</tr>
<tr>
<td></td>
<td>• $PaO_2/FiO_2 &lt;300$ mm Hg</td>
<td>• 37.5% of patients had a BMI &gt;30.</td>
<td></td>
</tr>
</tbody>
</table>
### Chloroquine, Hydroxychloroquine, or Ivermectin in Patients With Severe COVID-19

#### Study Design
- Involvement of >50% of lungs on CXR or CT

#### Key Exclusion Criteria:
- Aged <18 years old
- Cardiac arrhythmia, including prolonged QT interval
- Previous use of CQ, HCQ, or IVM for >24 hours

#### Interventions:
- CQ 450 mg twice daily on Day 0, then CQ 450 mg once daily for 4 days
- HCQ 400 mg twice daily on Day 0, then HCQ 400 mg once daily for 4 days
- IVM 14 mg once daily for 3 days followed by placebo for 2 days

#### Endpoints:
- Need for supplemental oxygen, invasive mechanical ventilation, or ICU admission
- Mortality

#### Results
- On admission, 76.5% of patients had respiratory failure, and 42.5% had “pneumonic syndrome.”

#### Outcomes:
- No differences between arms in proportion of patients who required supplemental oxygen (88.5% in CQ arm, 90.2% in HCQ arm, and 88.4% in IVM arm) or mean number of days of supplemental oxygenation (7.9 vs. 7.8 vs. 8.1 days)
- No differences between arms in proportion of patients who received invasive mechanical ventilation (20.6% vs. 21.1% vs. 23.5%)

#### Limitations and Interpretation
- No differences between arms in death due to COVID-19 complications (21.3% in CQ arm, 22.2% in HCQ arm, and 23.0% in IVM arm)
- Baseline characteristics that were associated with mortality included age >60 years (HR 2.44; 95% CI, 1.40–4.30), DM (HR 1.87; 95% CI, 1.02–2.59), BMI >33 (HR 1.95; 95% CI, 1.07–3.09), and SpO2 <90% (HR 5.79; 95% CI, 2.63–12.7).

### Ivermectin Versus Placebo for Outpatients With Mild COVID-19

#### Key Inclusion Criteria:
- SARS-CoV-2 PCR positive
- Mild disease

#### Key Exclusion Criteria:
- Severe symptoms likely related to cytokine storm
- Malignancy, chronic kidney disease, or cirrhosis
- Pregnancy

#### Number of Participants:
- IVM (n = 25) and control (n = 25)

#### Participant Characteristics:
- Mean age was 40.6 years.
- 62% of patients were male.
- 40% of patients had diabetes, 30% were smokers, 26% had hypertension, 8% had cardiovascular disease, and 12% had obesity.

#### Limitations:
- Small sample size
- Open-label study
- Authors reported the proportions of patients with certain symptoms and comorbidities but did not provide objective assessment of disease severity. This precludes the ability to compare outcomes between arms.
<table>
<thead>
<tr>
<th>Study Design</th>
<th>Methods</th>
<th>Results</th>
<th>Limitations and Interpretation</th>
</tr>
</thead>
</table>
| **Ivermectin Versus Placebo for Outpatients With Mild COVID-19**

### Interventions:
- IVM 12 mg PO immediately, followed by 12 mg doses at 12 and 24 hours, plus symptomatic treatment
- Symptomatic treatment

### Primary Endpoint:
- Symptoms reported on Day 7. Patients were stratified as asymptomatic or symptomatic.

### Outcomes:
- Proportion of asymptomatic patients at Day 7 was similar in IVM and control arms (64% vs. 60%; \( P = 0.500 \)).
- AEs were attributed to IVM in 8 patients (32%).

---

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Methods</th>
<th>Results</th>
<th>Limitations and Interpretation</th>
</tr>
</thead>
</table>
| **Ivermectin in Patients With Mild to Moderate COVID-19**

### Key Inclusion Criteria:
- Aged \( \geq 18 \) years
- Laboratory-confirmed SARS-CoV-2 infection
- \( \leq 7 \) days of symptoms
- Mild or moderate disease

### Key Exclusion Criteria:
- Hypersensitivity to IVM
- Pregnancy or breastfeeding
- Use of HCQ or “other antimicrobials”

### Interventions:
- Single dose of IVM 200 μg/kg
- SOC

### Key Limitations:
- Open-label study
- Small study
- Study enrolled young patients with mild disease who were unlikely to progress to severe COVID-19.

### Interpretation:
- Compared to SOC, use of IVM did not lead to faster recovery from mild to moderate COVID-19.
- The small sample size and large number of comparisons make it difficult to assess the clinical efficacy of IVM in this population.
<table>
<thead>
<tr>
<th>Study Design</th>
<th>Methods</th>
<th>Results</th>
<th>Limitations and Interpretation</th>
</tr>
</thead>
</table>
| RCT of outpatients with SARS-CoV-2 infection with or without symptoms in Bangladesh (n = 116) | Key Inclusion Criteria:  
- Laboratory-confirmed SARS-CoV-2 infection by RT-PCR  
- \( \text{SpO}_2 \geq 95\% \)  
- Normal or near-normal CXR  
- No unstable comorbidities | Number of Participants:  
Group A (n = 60) and Group B (n = 56) | Key Limitations:  
- Small sample size  
- Open-label study  
- No SOC alone group  
- Study enrolled young patients without major risk factors for disease progression.  
- None of the comparative outcome measures were statistically significant. |
| Interventions  
Group A:  
- A single dose of IVM 200 μg/kg plus DOX 100 mg twice daily for 10 days  
Group B:  
- HCQ 400 mg on Day 1, then HCQ 200 mg twice daily for 9 days plus AZM 500 mg once daily for 5 days | Participant Characteristics:  
- Mean age was 33.9 years.  
- 78% of patients were male.  
- 91 of 116 patients (78.5%) were symptomatic. | Interpretation:  
- In this small study with a young population, the authors suggested that IVM plus DOX was superior to HCQ plus AZM despite no statistically significant difference in time from recovery to negative PCR result and symptom recovery between patients who received IVM plus DOX and those who received HCQ plus AZM. |
| Primary Endpoints:  
- Time to negative PCR result. Asymptomatic patients were tested starting on Day 5, then every other day until a negative result occurred. Symptomatic patients were tested on their second symptom-free day, then every other day until a negative result occurred.  
- Time to resolution of symptoms | Outcomes:  
- PCR became negative in 60 of 60 patients (100%) in Group A and in 54 of 56 patients (96.4%) in Group B.  
- Mean time to negative PCR result: 8.93 days (range 8–13 days) in Group A, 9.33 days (range 5–15 days) in Group B \( (P = 0.2314) \).  
- Mean time to symptom recovery: 5.93 days (range 5–10 days) in Group A, 6.99 days (range 4–12 days) in Group B \( (P = 0.071) \).  
- In a subgroup analysis of patients who were symptomatic at baseline, the mean time to negative PCR result for Groups A and B were 9.06 days and 9.74 days, respectively \( (P = 0.0714) \).  
- Patients who received IVM plus DOX had fewer AEs than those who received HCQ plus AZM (31.7% vs. 46.4%) in the subgroup analysis. |
<table>
<thead>
<tr>
<th>Study Design</th>
<th>Methods</th>
<th>Results</th>
<th>Limitations and Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiviral Effect of High-Dose Ivermectin in Adults with COVID-19</strong>&lt;sup&gt;44&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multicenter, randomized, open-label, blinded trial of hospitalized adults with mild to moderate COVID-19 in Argentina (n = 45)</td>
<td><strong>Key Inclusion Criteria:</strong>&lt;br&gt;• Laboratory-confirmed SARS-CoV-2 infection&lt;br&gt;• Hospitalized&lt;br&gt;• ≤5 days of symptoms</td>
<td><strong>Number of Participants:</strong>&lt;br&gt;• IVM (n = 30) and SOC (n = 15)&lt;br&gt;• After excluding patients with poor sample quality, those without a detectable VL at baseline, and those who withdrew, 32 patients (20 IVM, 12 SOC) were included in the viral efficacy analysis population.</td>
<td><strong>Key Limitations:</strong>&lt;br&gt;• Small sample size&lt;br&gt;• No clinical response data reported.&lt;br&gt;• The C&lt;sub&gt;max&lt;/sub&gt; level of 160 ng/mL used in the analysis appears to be arbitrary.</td>
</tr>
<tr>
<td><strong>Key Exclusion Criteria:</strong>&lt;br&gt;• Use of immunomodulators or any agent with potential anti-SARS-CoV-2 activity prior to enrollment&lt;br&gt;• Poorly controlled comorbidities</td>
<td><strong>Participant Characteristics:</strong>&lt;br&gt;• Mean age was 42.3±12.8 years in IVM arm and 38.1±11.7 years in SOC arm.&lt;br&gt;• 50% of patients were male in IVM arm and 67% were male in SOC arm.</td>
<td><strong>Interpretation:</strong>&lt;br&gt;• Concentration-dependent virologic response was seen when using a higher-than-usual dose of IVM (600 μg/kg vs. 200 or 400 μg/kg once daily), with minimal associated toxicities.&lt;br&gt;• The study results showed large interpatient variation of IVM C&lt;sub&gt;max&lt;/sub&gt;. Larger sample sizes are needed to further assess the safety and efficacy of using higher doses of IVM to treat COVID-19.</td>
<td></td>
</tr>
<tr>
<td><strong>Interventions:</strong>&lt;br&gt;• IVM 600 μg/kg once daily plus SOC for 5 days&lt;br&gt;• SOC</td>
<td><strong>Primary Endpoints:</strong>&lt;br&gt;• By Day 5, a similar magnitude of VL reduction was seen in both arms.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PK Sampling:</strong>&lt;br&gt;• Performed 4 hours after dose on Days 1, 2, 3, 5, and 7 to assess elimination</td>
<td><strong>Other Outcomes:</strong>&lt;br&gt;• Patients with higher IVM concentrations had greater reductions in VL (r 0.44; P &lt; 0.04).&lt;br&gt;• Treated patients were divided into 2 groups based on IVM C&lt;sub&gt;max&lt;/sub&gt;: IVM &gt;160 ng/mL (median of 202 ng/mL) and &lt;160 ng/mL (median of 109 ng/mL).&lt;br&gt;• Median percentage of VL reduction by C&lt;sub&gt;max&lt;/sub&gt; concentration vs. control (P = 0.0096) was 72% (IQR 59% to 77%) in &gt;160 ng/mL group (n = 9), 40% (IQR 21% to 46%) in &lt;160 ng/mL group (n = 11), and 42% (IQR 31% to 73%) in SOC arm.&lt;br&gt;• Median viral decay rate (P = 0.04) was 0.64 day&lt;sup&gt;-1&lt;/sup&gt; in &gt;160 ng/mL group, 0.14 day&lt;sup&gt;-1&lt;/sup&gt; in &lt;160 ng/mL group, and 0.13 day&lt;sup&gt;-1&lt;/sup&gt; in SOC arm.&lt;br&gt;• Percentages of AEs were similar between the arms (43% in IVM arm, 33% in SOC arm), and AEs were mostly mild.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Study Design
A single-center, randomized, double-blind, placebo-controlled pilot trial in Spain (n = 24)

### Key Inclusion Criteria:
- Laboratory-confirmed SARS-CoV-2 infection
- ≤72 hours of symptoms
- No risk factors for severe disease or COVID-19 pneumonia

### Interventions:
- Single dose of IVM 400 μg/kg
- Nonmatching placebo tablet administered by a nurse who did not participate in the patient's care

### Primary Endpoint:
- Positive SARS-CoV-2 PCR result from an NP swab at Day 7 post-treatment

### Number of Participants:
- IVM (n = 12) and placebo (n = 12)

### Participant Characteristics:
- Mean age was 26 years (range 18–54 years).
- 50% of patients were male.
- All patients had symptoms at baseline; 70% had headache, 66% had fever, 58% had malaise, and 25% had cough.
- Median onset of symptoms was 24 hours in IVM arm and 48 hours in placebo arm.

### Outcomes:
- At Day 7, 12 patients (100%) in both groups had a positive PCR (for gene N), and 11 of 12 who received IVM (92%) and 12 of 12 who received placebo (100%) had a positive PCR (for gene E); \( P = 1.0 \) for both comparisons.
- In a post hoc analysis, the authors reported fewer patient-days of cough and anosmia in the IVM-treated patients, but no differences in the patient-days for fever, general malaise, headache, and nasal congestion.

### Key Limitations:
- Small sample size
- PCR is not a validated surrogate marker for clinical efficacy.
- PCR cycle threshold values were higher for patients who received IVM than those who received placebo at some time points, but these comparisons are not statistically significant.
- Symptom results were not a prespecified outcome and are of unclear statistical and clinical significance.

### Interpretation:
- Patients who received IVM showed no difference in viral clearance compared to those who received placebo.
- The small sample size and large number of comparisons make it difficult to assess the clinical efficacy of IVM in this population.

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Methods</th>
<th>Results</th>
<th>Limitations and Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>A single-center, randomized, double-blind, placebo-controlled pilot trial in Spain (n = 24)</td>
<td><strong>Key Inclusion Criteria:</strong>&lt;br&gt;- Laboratory-confirmed SARS-CoV-2 infection&lt;br&gt;- ≤72 hours of symptoms&lt;br&gt;- No risk factors for severe disease or COVID-19 pneumonia</td>
<td><strong>Number of Participants:</strong>&lt;br&gt;- IVM (n = 12) and placebo (n = 12)</td>
<td><strong>Key Limitations:</strong>&lt;br&gt;- Small sample size&lt;br&gt;- PCR is not a validated surrogate marker for clinical efficacy.&lt;br&gt;- PCR cycle threshold values were higher for patients who received IVM than those who received placebo at some time points, but these comparisons are not statistically significant.&lt;br&gt;- Symptom results were not a prespecified outcome and are of unclear statistical and clinical significance.&lt;br&gt;- Patients who received IVM showed no difference in viral clearance compared to those who received placebo.</td>
</tr>
<tr>
<td>Study Design</td>
<td>Methods</td>
<td>Results</td>
<td>Limitations and Interpretation</td>
</tr>
<tr>
<td>-------------</td>
<td>---------</td>
<td>---------</td>
<td>--------------------------------</td>
</tr>
</tbody>
</table>
| Randomized, unblinded, single-center study of patients with laboratory-confirmed SARS-CoV-2 infection in Baghdad, Iraq (n = 140) | Key Inclusion Criteria:  
- Diagnosis by clinical, radiological, and PCR testing  
- Outpatients had mild or moderate COVID-19, while inpatients had severe and critical COVID-19. | Number of Participants:  
- IVM plus DOX plus standard therapy (n = 70) and standard therapy alone (n = 70) | Key Limitations:  
- Not blinded  
- Patient deaths prevent an accurate comparison of mean recovery time between arms in this study, and the authors did not account for competing mortality risks.  
- Relies heavily on post hoc subgroup comparisons.  
- Substantial imbalance in disease severity at baseline  
- Authors noted that critical patients were not assigned to standard therapy arm; thus, the arms were not truly randomized.  
- Unclear how many patients required corticosteroids. |
| | Interventions:  
- IVM 200 μg/kg PO daily for 2 days. If patient required more time to recover, a third dose was given 7 days after the first dose, plus DOX 100 mg twice daily for 5–10 days plus standard therapy (based on clinical condition).  
- Standard therapy was based on clinical condition and included AZM, acetaminophen, vitamin C, zinc, vitamin D3, dexamethasone 6 mg daily or methylprednisolone 40 mg twice daily if needed, and oxygen or mechanical ventilation if needed.  
- All critically ill patients were assigned to receive IVM plus DOX. | Participant Characteristics:  
- Median age was 50 years in IVM arm and 47 years in standard therapy arm.  
- 50% of patients were male in IVM arm and 53% were male in standard therapy arm.  
- In IVM arm, 48 patients had mild or moderate COVID-19, 11 had severe COVID-19, and 11 had critical COVID-19.  
- In standard therapy arm, 48 patients had mild or moderate COVID-19, 22 had severe COVID-19, and no patients had critical COVID-19. | Interpretation:  
- IVM may shorten the time to recovery for patients with mild or moderate disease, but the lack of control for competing mortality causes in the study limits the ability to interpret the results. |
| | Outcomes:  
- Mean recovery time in IVM arm was 10.1 days (SD 5.3 days) vs. 17.9 days (SD 6.8 days) for standard therapy arm (P < 0.0001). This result was only significant for those with mild to moderate disease.  
- Disease progression occurred in 3 of 70 patients (4.3%) in IVM arm and 7 of 70 (10.0%) in standard therapy arm (P = 0.19)  
- 2 of 70 patients (2.85%) in IVM arm and 6 of 70 (8.57%) in standard therapy arm died (P = 0.14) | |

This is a preliminary report that has not yet been peer reviewed.
<table>
<thead>
<tr>
<th>Study Design</th>
<th>Methods</th>
<th>Results</th>
<th>Limitations and Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivermectin in Patients With Mild to Moderate COVID-19&lt;sup&gt;27&lt;/sup&gt;</td>
<td>Key Inclusion Criteria:</td>
<td>Number of Participants:</td>
<td>Key Limitations:</td>
</tr>
<tr>
<td>Double-blind RCT in patients with mild to moderate COVID-19 in India (n = 157)</td>
<td>• Aged ≥18 years</td>
<td>• ITT analysis (safety): IVM 24 mg (n = 51), IVM 12 mg (n = 49), and placebo (n = 52)</td>
<td>• Small sample size</td>
</tr>
<tr>
<td></td>
<td>• Positive SARS-CoV-2 RT-PCR or antigen test</td>
<td>• mITT analysis (included only those with positive NP/OP RT-PCR result): IVM 24 mg (n = 40), IVM 12 mg (n = 40), and placebo (n = 45)</td>
<td>Interpretation:</td>
</tr>
<tr>
<td></td>
<td>• Nonsevere COVID-19 (defined as SpO&lt;sub&gt;2&lt;/sub&gt; &gt;90% on RA and no</td>
<td>• 64% of patients had mild disease (including asymptomatic disease) and 36% had moderate disease</td>
<td>• Though the rate of negative RT-PCR results was numerically higher in the IVM arms than in the placebo arm on Day 5, the result was not statistically significant.</td>
</tr>
<tr>
<td></td>
<td>hypotension or need for mechanical ventilation)</td>
<td></td>
<td>• No difference in clinical outcomes or frequency of AEs.</td>
</tr>
<tr>
<td></td>
<td>Key Exclusion Criteria:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• CrCl &lt;30 mL/min</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Transaminases &gt;5 times ULN</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• MI or heart failure in previous 90 days</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• QTc interval &gt;450 ms</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Severe comorbidity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interventions:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Single dose of IVM 24 mg in alcohol-based elixir prepared by pharmacy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Single dose of same elixir with IVM 12 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Single dose of same elixir without IVM (placebo)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary Endpoint:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Reduction of SARS-CoV-2 VL as measured by NP and OP swab at Day 5</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Conversion to negative RT-PCR at Day 5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key Secondary Endpoints:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Qualitative and quantitative RT-PCR on Days 3 and 7</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Time to clinical resolution</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Ivermectin 24 mg administered as a single dose in an alcohol-based elixir.*
<table>
<thead>
<tr>
<th>Study Design</th>
<th>Methods</th>
<th>Results</th>
<th>Limitations and Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ivermectin in Patients With Mild to Moderate COVID-19</strong>&lt;sup&gt;27&lt;/sup&gt;, continued</td>
<td>• Frequency of clinical worsening</td>
<td>• No difference between arms in frequency of AEs or SAEs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Clinical status at Day 14</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Number of hospital-free days at Day 28</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Efficacy and Safety of Ivermectin and Hydroxychloroquine in Patients With Severe COVID-19</strong>&lt;sup&gt;28&lt;/sup&gt;</td>
<td>Randomized, double-blind trial of hospitalized adults with COVID-19 pneumonia in Mexico (n = 106)</td>
<td><strong>Key Inclusion Criteria:</strong></td>
<td><strong>Key Limitations:</strong></td>
</tr>
<tr>
<td></td>
<td>* Laboratory-confirmed SARS-CoV-2 infection</td>
<td>• Laboratory-confirmed SARS-CoV-2 infection</td>
<td>• Small study</td>
</tr>
<tr>
<td></td>
<td>* Pneumonia, diagnosed by CXR or high-resolution chest CT scan</td>
<td>* Pneumonia, diagnosed by CXR or high-resolution chest CT scan</td>
<td>• Length of follow-up period is unclear.</td>
</tr>
<tr>
<td></td>
<td>* Recently established hypoxemic respiratory failure or deterioration of pre-existing lung or heart disease</td>
<td>* Recently established hypoxemic respiratory failure or deterioration of pre-existing lung or heart disease</td>
<td>• The study was stopped prior to achieving its target sample size.</td>
</tr>
<tr>
<td><strong>Key Exclusion Criteria:</strong></td>
<td>• Receipt of HFNC oxygen or invasive mechanical ventilation</td>
<td><strong>Participant Characteristics:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Patients with QT intervals $\geq 500$ ms were not eligible for HCQ but were eligible for IVM.</td>
<td>• Mean age was 53 years (SD 16.9 years).</td>
<td></td>
</tr>
<tr>
<td><strong>Interventions:</strong></td>
<td>• HCQ 400 mg twice daily on Day 1, then HCQ 200 mg/kg twice daily for 4 days</td>
<td>• 62% of patients were male.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Single dose of IVM 12 mg (in patients weighing $\leq 80$ kg) or 18 mg (in those weighing $&gt;80$ kg) plus calcium citrate for subsequent doses</td>
<td>• 34% of patients had diabetes, 32% had hypertension, and 72% had any comorbidity.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Calcium citrate placebo</td>
<td>• Mean BMI was 29.6 (SD 6.6).</td>
<td></td>
</tr>
<tr>
<td><strong>Primary Endpoint:</strong></td>
<td>• Time to discharge due to recovery</td>
<td><strong>Outcomes:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Median time to discharge due to recovery was 7 days (IQR 3–9 days) in HCQ arm, 6 days (IQR 4–11 days) in IVM arm, and 5 days (IQR 4–7 days) in placebo arm. The differences between arms were not statistically significant.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Proportion of patients discharged alive: 79% in HCQ arm, 75% in IVM arm, and 73% in placebo arm</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Mortality: 6% of patients in HCQ arm, 14% in IVM arm, and 16% in placebo arm</td>
<td></td>
</tr>
</tbody>
</table>
## Study Design

Randomized, double-blind, placebo-controlled, multicenter, Phase 2 clinical trial of hospitalized adults with mild to severe SARS-CoV-2 infection in 5 facilities in Iran (n = 180)

*This is a preliminary report that has not yet been peer reviewed.*

## Methods

### Key Inclusion Criteria:
- Symptoms suggestive of COVID-19 pneumonia, with chest CT compatible with mild to severe COVID-19 or positive RT-PCR result for SARS-CoV-2

### Key Exclusion Criteria:
- Severe immunosuppression, malignancy, or chronic kidney disease
- Pregnancy

### Interventions:
- HCQ 200 mg/kg twice daily alone as SOC (standard arm)
- SOC plus 1 of the following:
  - Placebo
  - Single dose of IVM 200 μg/kg
  - IVM 200 μg/kg on Days 1, 3, and 5
  - Single dose of IVM 400 μg/kg
  - IVM 400 μg/kg on Day 1, then IVM 200 μg/kg on Days 3 and 5

### Primary Endpoint:
- Clinical recovery within 45 days of enrollment (defined as normal temperature, respiratory rate, and SpO₂ >94% for 24 hours)

## Results

### Number of Participants:
- All 6 arms (n = 30 in each arm)

### Participant Characteristics:
- Average age was 56 years (range 45–67 years).
- 50% of patients were male.
- Disease stratification (based on CT findings): negative (1%), mild (14%), moderate (73%), and severe (12%)
- Mean SpO₂ at baseline was 89%.

### Primary Outcomes:
- Durations of hypoxemia and hospitalization were shorter in IVM arms than placebo arm (\(P = 0.025\) and \(P = 0.006\), respectively), and mortality was lower in the IVM arms (\(P = 0.001\)).
- There was no difference in number of days of tachypnea (\(P = 0.584\)) or return to normal temperature (\(P = 0.102\)).
- Significant differences in change from baseline to Day 5 in absolute lymphocyte count, platelet count, erythrocyte sedimentation rate, and CRP.
- Higher mortality was reported in standard and placebo arms than IVM arms.

## Limitations and Interpretation

### Key Limitations:
- Small study
- Power estimation is confusing.
- Mortality was not listed as the primary or secondary outcome.
- It is unclear whether IVM patients also received HCQ.
- It is unclear whether the between-group comparisons are between combined IVM groups and placebo plus SOC.
- Patients were stratified by disease severity based on CT findings. These categorizations are unclear and were not taken into account in outcome comparisons.
- The post hoc grouping of randomized arms raises risk of false positive findings.

### Interpretation:
- IVM appeared to improve laboratory outcomes and some clinical outcomes (shorter duration of hypoxemia and hospitalization) and lowered mortality.
- The small size of the study, the unclear treatment arm assignments, and the lack of accounting for disease severity at baseline make it difficult to draw conclusions about the efficacy of using IVM to treat patients with mild COVID-19.
### Study Design
Retrospective analysis of consecutive patients with laboratory-confirmed SARS-CoV-2 infection who were admitted to 4 Florida hospitals (n = 276)

### Methods

**Key Inclusion Criteria:**
- Positive NP swab with SARS-CoV-2 RNA

**Interventions:**
- Single dose of IVM 200 μg/kg, repeated on Day 7 at the doctors’ discretion; 90% of patients also received HCQ.
- Usual care: 97% of patients received HCQ and most also received AZM.

**Primary Endpoint:**
- All-cause, in-hospital mortality

### Results

**Number of Participants:**
- IVM (n = 173; 160 patients received a single dose, 13 patients received a second dose) and usual care (n = 103)

**Participant Characteristics:**
- Mean age was 60.2 years in IVM arm and 58.6 years in usual care arm.
- 51.4% of patients were male in IVM arm and 58.8% were male in usual care arm.
- 56.6% of patients were Black in IVM arm and 51.4% were Black in usual care arm.

**Outcomes:**
- All-cause mortality was lower in IVM arm than in usual care arm (OR 0.27; 95% CI, 0.09–0.80; *P* = 0.03); the benefit appeared to be limited to the subgroup of patients with severe disease.
- No difference in median length of hospital stay between arms (7 days for both) or proportion of mechanically ventilated patients who were successfully extubated (36% in IVM arm vs. 15% in usual care arm; *P* = 0.07).

### Limitations and Interpretation

**Key Limitations:**
- Not randomized
- Little to no information on SpO₂ or radiographic findings
- Timing of therapeutic interventions was not standardized.
- Ventilation and hospitalization duration analyses do not appear to account for death as a competing risk.
- No virologic assessments were performed.

**Interpretation:**
- IVM use was associated with lower mortality than usual care. However, the limitations of this retrospective analysis make it difficult to draw conclusions about the efficacy of using IVM to treat patients with COVID-19.
# Study Design
Retrospective cohort study of hospitalized adults with COVID-19 in Peru (n = 5,683)

*This is a preliminary report that has not yet been peer-reviewed.*

## Methods
### Key Inclusion Criteria:
- Aged ≥18 years
- Symptomatic
- Laboratory-confirmed SARS-CoV-2 infection
- No life-threatening illness at admission

### Key Exclusion Criteria:
- Required oxygen at admission
- Use of tocilizumab, LPV/RTV, or RDV

## Interventions:
- One of the following interventions administered within 48 hours of admission:
  - HCQ or CQ alone
  - IVM alone
  - AZM alone
  - HCQ or CQ plus AZM
  - IVM plus AZM
  - SOC (e.g., supportive care, antipyretics, hydration)

## Primary Endpoint:
- All-cause mortality

## Secondary Endpoint:
- All-cause mortality and/or transfer to ICU

## Number of Participants:
- HCQ or CQ alone (n = 200), IVM alone (n = 203), AZM alone (n = 1,600), HCQ or CQ plus AZM (n = 692), IVM plus AZM (n = 358), and SOC (n = 2,630)

## Participant Characteristics:
- 63% of patients were male.
- Mean age was 59.4 years (range 18–104 years).
- All patients had mild or moderate disease.

## Outcomes:
- Median follow-up time was 7 days. Mortality rate was 18.9% at the end of follow-up.
- IVM alone was associated with increased risk of death and/or ICU transfer compared to SOC (wHR 1.58; 95% CI, 1.11–2.25).
- IVM plus AZM did not have an effect on deaths or any secondary outcomes (all-cause death and/or ICU transfer, all-cause death and/or oxygen prescription) compared to SOC.
- HCQ or CQ plus AZM was associated with a higher risk of death (wHR 1.84; 95% CI, 1.12–3.02), death and/or ICU transfer (wHR 1.49; 95% CI, 1.01–2.19), and death and/or oxygen prescription (wHR 1.70; 95% CI, 1.07–2.69) compared to SOC.

## Limitations and Interpretation
### Key Limitations:
- Not randomized
- Unclear whether all patients received IVM or other medications according to Peruvian guidelines referred to in the manuscript.
- Dosing and timing of administration are unclear.

### Interpretation:
- Compared to SOC, IVM alone was associated with increased risk of death and/or ICU admission. Using IVM in combination with AZM was not associated with effects on mortality, ICU transfer, or oxygen prescription compared to SOC.
Retrospective Study of Ivermectin Versus Standard of Care in Patients With COVID-19

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Methods</th>
<th>Results</th>
<th>Limitations and Interpretation</th>
</tr>
</thead>
</table>
| Retrospective study of consecutive adult patients hospitalized in Bangladesh with laboratory-confirmed SARS-CoV-2 infection (n = 248) | Key Inclusion Criteria:  
- Aged ≥18 years  
- Positive NP swab with SARS-CoV-2 RNA  
- “Free from any other serious pathological conditions” | Number of Participants:  
- IVM (n = 115) and SOC (n = 133) | Key Limitations:  
- Not randomized  
- Disease severity at admission was reported as mild or moderate, but 12% of patients in IVM arm and 9% in SOC arm had SpO₂ <94%  
- Even though only 10% of patients developed pneumonia, 60% received antibiotics  
- Possibility of harm from concomitant medications |
| Interventions:  
- Single dose of IVM 12 mg within 24 hours of hospital admission  
- SOC | Participant Characteristics:  
- Median age in IVM arm was 34 years; 70% of patients were male.  
- Median age in SOC arm was 35 years; 52% of patients were male.  
- All patients had mild or moderate disease.  
- 12% of patients had hypertension in both arms.  
- 17% of patients in IVM arm and 12% in SOC arm had DM. | Primary Outcome:  
- Not specified | Interpretation:  
- Compared to SOC, IVM use was associated with faster rates of viral clearance and better clinical outcomes, including shorter hospital stay and lower mortality. |
| Outcomes:  
- Fewer patients in IVM arm had evidence of disease progression compared to SOC arm (P < 0.001): moderate respiratory distress (2.6% vs. 15.8%), pneumonia (0% vs. 9.8%), ischemic stroke (0% vs. 1.5%).  
- Fewer patients in IVM arm required intensive care management compared to SOC arm (0.9% vs. 8.8%; P < 0.001).  
- Fewer patients in IVM arm required antibiotic therapy (15.7% vs. 60.2%; P < 0.001) or supplemental oxygen (9.6% vs. 45.9%; P < 0.001) compared to SOC arm.  
- Shorter median duration of viral clearance in IVM arm compared to SOC arm (4 vs. 15 days; P < 0.001).  
- Shorter median duration of hospital stay in IVM arm compared to SOC arm (9 vs. 15 days; P < 0.001).  
- Lower mortality in IVM arm compared to SOC arm (0.9% vs. 6.8%; P < 0.05) |
References


5. Cadegiani FA, Goren A, Wambier CG, McCoy J. Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly reduced symptoms compared to known outcomes in untreated patients. medRxiv. 2020;Preprint. Available at: https://www.medrxiv.org/content/10.1101/2020.10.29.20222505v1.


Lopinavir/Ritonavir and Other HIV Protease Inhibitors

*Last Updated: February 11, 2021*

The replication of SARS-CoV-2 depends on the cleavage of polyproteins into an RNA-dependent RNA polymerase and a helicase.¹ Two proteases are responsible for this cleavage: 3-chymotrypsin-like protease (3CLpro) and papain-like protease (PLpro).

Lopinavir/ritonavir and darunavir/cobicistat have been studied in patients with COVID-19. The clinical trials discussed below have not demonstrated a clinical benefit for protease inhibitors in patients with COVID-19.

**Recommendations**

- The COVID-19 Treatment Guidelines Panel (the Panel) **recommends against** the use of *lopinavir/ritonavir* and *other HIV protease inhibitors* for the treatment of COVID-19 in hospitalized patients (AI).
- The Panel **recommends against** the use of *lopinavir/ritonavir* and *other HIV protease inhibitors* for the treatment of COVID-19 in nonhospitalized patients (AIII).

**Rationale**

The pharmacodynamics of lopinavir/ritonavir raise concerns about whether it is possible to achieve drug concentrations that can inhibit the SARS-CoV-2 proteases.²³ In addition, lopinavir/ritonavir did not show efficacy in two large randomized controlled trials in hospitalized patients with COVID-19.⁴⁵

There is currently a lack of data on the use of lopinavir/ritonavir in nonhospitalized patients with COVID-19. However, the pharmacodynamic concerns and the lack of evidence for a clinical benefit among hospitalized patients with COVID-19 undermine confidence that lopinavir/ritonavir has a clinical benefit at any stage of SARS-CoV-2 infection.

**Adverse Events**

The adverse events for lopinavir/ritonavir include:

- Nausea, vomiting, diarrhea (common)
- QTc prolongation
- Hepatotoxicity

**Drug-Drug Interactions**

Lopinavir/ritonavir is a potent inhibitor of cytochrome P450 3A. Coadministering lopinavir/ritonavir with medications that are metabolized by this enzyme may increase the concentrations of those medications, resulting in concentration-related toxicities. Please refer to the *Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV* for a list of potential drug interactions.

**Summary of Clinical Data for COVID-19**

- The plasma drug concentrations achieved using typical doses of lopinavir/ritonavir are far below the levels that may be needed to inhibit SARS-CoV-2 replication.³
- Lopinavir/ritonavir did not demonstrate a clinical benefit in hospitalized patients with COVID-19 during a large randomized trial in the United Kingdom.⁴
• In a large international randomized trial, lopinavir/ritonavir did not reduce the mortality rate among hospitalized patients with COVID-19.\(^5\)
• A moderately sized randomized trial (n = 199) failed to find a virologic or clinical benefit of lopinavir/ritonavir over standard of care.\(^6\)
• Results from a small randomized controlled trial showed that darunavir/cobicistat was not effective for the treatment of COVID-19.\(^7\)
• There are no data from clinical trials that support using other HIV protease inhibitors to treat COVID-19.
• Please see Clinical Data for COVID-19 below for more information.

Clinical Data for COVID-19

The information presented in this section may include data from preprints or articles that have not been peer reviewed. This section will be updated as new information becomes available. Please see ClinicalTrials.gov for more information on clinical trials that are evaluating lopinavir/ritonavir.

Lopinavir/Ritonavir in Hospitalized Patients With COVID-19: The RECOVERY Trial

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is an ongoing, open-label, randomized controlled trial with multiple arms, including a control arm; in one arm, participants received lopinavir/ritonavir. The trial was conducted across 176 hospitals in the United Kingdom and enrolled hospitalized patients with clinically suspected or laboratory-confirmed SARS-CoV-2 infection.\(^4\)

Patients were randomized into several parallel treatment arms; this included randomization in a 2:1 ratio to receive either the usual standard of care only or the usual standard of care plus lopinavir 400 mg/ritonavir 100 mg orally every 12 hours for 10 days or until hospital discharge. Patients who had severe hepatic insufficiency or who were receiving medications that had potentially serious or life-threatening interactions with lopinavir/ritonavir were excluded from randomization into either of these arms. Mechanically ventilated patients were also underrepresented in this study because it was difficult to administer the oral tablet formulation of lopinavir/ritonavir to patients who were on mechanical ventilation. The primary outcome was all-cause mortality at Day 28 after randomization.

The lopinavir/ritonavir arm was discontinued on June 29, 2020, after the independent data monitoring committee concluded that the data showed no clinical benefit for lopinavir/ritonavir.

Patient Characteristics

• Of the 7,825 participants who were eligible to receive lopinavir/ritonavir, 1,616 were randomized to receive lopinavir/ritonavir and 3,424 were randomized to receive standard of care only. The remaining participants were randomized to other treatment arms in the study.
• In both the lopinavir/ritonavir arm and the standard of care arm, the mean age was 66 years; 44% of patients were aged ≥70 years.
• Test results for SARS-CoV-2 infection were positive for 88% of patients. The remaining 12% had a negative test result.
• Comorbidities were common; 57% of patients had at least one major comorbidity. Of those patients, 28% had diabetes mellitus, 26% had heart disease, and 24% had chronic lung disease.
• At randomization, 4% of patients were receiving invasive mechanical ventilation, 70% were receiving oxygen only (with or without noninvasive ventilation), and 26% were receiving neither.
• The percentages of patients who received azithromycin or another macrolide during the follow-up
period were similar in both arms (23% in the lopinavir/ritonavir arm vs. 25% in the standard of care arm). In addition, 10% of patients in both arms received dexamethasone.

Results

• There was no significant difference in the primary outcome of 28-day mortality between the two arms; 374 patients (23%) in the lopinavir/ritonavir arm and 767 patients (22%) in the standard of care arm had died by Day 28 (rate ratio 1.03; 95% CI, 0.91–1.17; \( P = 0.60 \)).

• A similar 28-day mortality was reported for patients who received lopinavir/ritonavir in an analysis that was restricted to the 4,423 participants who had positive SARS-CoV-2 test results (rate ratio 1.05; 95% CI, 0.92–1.19; \( P = 0.49 \)).

• Patients in the lopinavir/ritonavir arm and patients in the standard of care arm had similar median times to discharge (11 days in both arms) and similar probabilities of being discharged alive within 28 days (69% vs. 70%).

• Among participants who were not on invasive mechanical ventilation at baseline, patients who received lopinavir/ritonavir and those who received standard of care only had similar risks of progression to intubation or death.

• Results were consistent across subgroups defined by age, sex, ethnicity, or respiratory support at baseline.

Limitations

• The study was not blinded.

• No laboratory or virologic data were collected.

Interpretation

Lopinavir/ritonavir did not decrease 28-day all-cause mortality when compared to the usual standard of care in hospitalized persons with clinically suspected or laboratory-confirmed SARS-CoV-2 infection. Participants who received lopinavir/ritonavir and those who received standard of care only had similar median lengths of hospital stay. Among the patients who were not on invasive mechanical ventilation at the time of randomization, those who received lopinavir/ritonavir were as likely to require intubation or die during hospitalization as those who received standard of care.

Lopinavir/Ritonavir in Hospitalized Patients with COVID-19: The Solidarity Trial

The Solidarity trial was an open-label, randomized controlled trial that enrolled hospitalized patients with COVID-19 in 405 hospitals across 30 countries. The study included multiple arms; in one arm, participants received lopinavir/ritonavir. The control group for this arm included people who were randomized at the same site and time who could have received lopinavir/ritonavir but received standard of care instead. Lopinavir 400 mg/ritonavir 100 mg was administered orally twice daily for 14 days or until hospital discharge. Only the oral tablet formulation of lopinavir/ritonavir was available, which precluded administration to those on mechanical ventilation. The primary outcome was in-hospital mortality.\(^5\)

After the results of the RECOVERY trial prompted a review of the Solidarity data, the lopinavir/ritonavir arm ended enrollment on July 4, 2020. At that time, 1,411 patients had been randomized to receive lopinavir/ritonavir, and 1,380 patients received standard of care.

Patient Characteristics

• In both the lopinavir/ritonavir arm and the standard of care arm, 20% of the participants were aged \( \geq 70 \) years and 37% were aged \( <50 \) years.

• Comorbidities were common. Diabetes mellitus was present in 24% of patients, heart disease in 21%, and chronic lung disease in 7%.
• At randomization, 8% of patients were receiving invasive mechanical ventilation or extracorporeal membrane oxygenation, 53% were receiving oxygen only (with or without noninvasive ventilation), and 39% were receiving neither.
• Similar percentages of patients received corticosteroids in the lopinavir/ritonavir arm and the standard of care arm (23% vs. 24%). Other nonstudy treatments were administered less often, and the use of these treatments was balanced between arms.

Results
• There was no significant difference in in-hospital mortality between the two arms; 148 patients (9.7%) in the lopinavir/ritonavir arm and 146 patients (10.3%) in the standard of care arm had died by Day 28 (rate ratio 1.00; 95% CI, 0.79–1.25; \( P = 0.97 \)).
• Progression to mechanical ventilation among those who were not ventilated at randomization occurred in 126 patients in the lopinavir/ritonavir arm and 121 patients in the standard of care arm.
• In-hospital mortality results appeared to be consistent across subgroups.

Limitations
• The study was not blinded.
• Those who were on mechanical ventilation were unable to receive lopinavir/ritonavir.
• The study includes no data on time to recovery.

Interpretation
Among hospitalized patients, lopinavir/ritonavir did not decrease in-hospital mortality or the number of patients who progressed to mechanical ventilation compared to standard of care.

Lopinavir/Ritonavir Pharmacokinetics in Patients With COVID-19
In a case series, eight patients with COVID-19 were treated with lopinavir 400 mg/ritonavir 100 mg orally twice daily and had plasma trough levels of lopinavir drawn and assayed by liquid chromatography-tandem mass spectrometry.\(^3\)

Results
• The median plasma lopinavir concentration was 13.6 μg/mL.
• After correcting for protein binding, trough levels would need to be approximately 60-fold to 120-fold higher to achieve the in vitro half-maximal effective concentration (EC\(_{50}\)) for SARS-CoV-2.

Limitations
• Only the trough levels of lopinavir were quantified.
• The concentration of lopinavir required to effectively inhibit SARS-CoV-2 replication in vivo is currently unknown.

Interpretation
The plasma drug concentrations that were achieved using typical doses of lopinavir/ritonavir are far below the levels that may be needed to inhibit SARS-CoV-2 replication.

Other Reviewed Studies
The Panel has reviewed other clinical studies that evaluated the use of protease inhibitors for the treatment of COVID-19.\(^6,8,9\) These studies have limitations that make them less definitive and
informative than larger randomized clinical trials. The Panel’s summaries and interpretations of some of these studies are available in the archived versions of the Guidelines.

References


Nitazoxanide

Last Updated: July 8, 2021

Nitazoxanide is a broad-spectrum thiazolide antiparasitic agent that is approved by the Food and Drug Administration (FDA) for the treatment of *Cryptosporidium parvum* and *Giardia duodenalis* infections in children aged ≥1 year and adults. Nitazoxanide is rapidly metabolized to its active metabolite, tizoxanide, and has in vitro antiviral activity against a range of viruses, including influenza viruses, hepatitis B and C viruses, norovirus, rotavirus, Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2.1-3 The mechanism of antiviral activity is not fully characterized. Nitazoxanide inhibits host enzymes, which impairs the posttranslational processing of viral proteins. It also has inhibitory effects on proinflammatory cytokines. With the exception of a Phase 2b/3 trial for uncomplicated influenza, the evidence for clinical activity of nitazoxanide against other viruses is limited or of low quality.4

**Recommendation**

- The COVID-19 Treatment Guidelines Panel (the Panel) **recommends against** the use of nitazoxanide for the treatment of COVID-19, except in a clinical trial (BIIa).

**Rationale**

Two randomized controlled trials that were conducted in Brazil and the United States did not find a significant clinical benefit for nitazoxanide treatment in nonhospitalized adults with COVID-19 when treatment was initiated within 2 to 5 days after illness onset.5,6 One of these trials, which has not yet been published, reported that fewer patients in the nitazoxanide arm progressed to severe COVID-19 than in the placebo arm. However, the study was underpowered to detect a difference, and this finding was not statistically significant.6 Additional small, unpublished studies were reviewed; however, due to their limitations, they did not provide support for the use of nitazoxanide.7,8 Nitazoxanide was well tolerated in these trials. The Panel concluded that results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of nitazoxanide in the treatment of COVID-19.

Please see **Table 2d** for more information.

**Monitoring, Adverse Effects, and Drug-Drug Interactions**

- Nitazoxanide is generally well tolerated. The most commonly reported side effects include abdominal pain, diarrhea, headache, nausea, vomiting, urine discoloration, and, rarely, ocular discoloration.
- Nitazoxanide is a highly plasma protein-bound drug (>99.9%). Drug-drug interactions may occur when nitazoxanide is administered concurrently with other highly plasma protein-bound drugs due to competition for binding sites. If nitazoxanide is coadministered with other highly protein-bound drugs with narrow therapeutic indices, monitor the patient for adverse drug reactions.
- Please see **Table 2e** for more information.

**Considerations in Pregnancy**

According to the animal study data included in the product label, nitazoxanide does not appear to affect fertility, nor does it cause fetal toxicity.9 There are no data on using nitazoxanide to treat COVID-19 in pregnant women.


**Considerations in Children**

Nitazoxanide is approved by the FDA for use in children aged ≥1 year old to treat *Cryptosporidium parvum* and *Giardia duodenalis* infections. Dosing for the nitazoxanide suspension or tablets is available for children that provides exposure that is similar to the approved adult dose of oral nitazoxanide 500 mg twice daily. There are no data on using nitazoxanide to treat COVID-19 in children.

**Clinical Trials**

Several clinical trials that are evaluating the use of nitazoxanide for the treatment of COVID-19 are currently underway or in development. Please see [ClinicalTrials.gov](https://clinicaltrials.gov) for the latest information.

**References**


### Table 2d. Nitazoxanide: Selected Clinical Data

**Last Updated: July 8, 2021**

The information in this table may include data from preprints or articles that have not been peer reviewed. This section will be updated as new information becomes available. Please see [ClinicalTrials.gov](https://clinicaltrials.gov) for more information on clinical trials that are evaluating NTZ for the treatment of COVID-19. The clinical trials described in this table do not represent all the trials that the Panel reviewed while developing recommendations for NTZ.¹²

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Methods</th>
<th>Results</th>
<th>Limitations and Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Treatment of Mild COVID-19 with Nitazoxanide³</td>
<td><strong>Key Inclusion Criteria:</strong></td>
<td><strong>Number of Participants:</strong></td>
<td><strong>Key Limitations:</strong></td>
</tr>
<tr>
<td>Randomized, double-blind, placebo-controlled trial in nonhospitalized adults with mild COVID-19 in Brazil (n = 475)</td>
<td>• Clinical signs and symptoms of COVID-19 for ≤3 days (fever, dry cough, and/or fatigue)</td>
<td>• NTZ (n = 194) and placebo (n = 198)</td>
<td>• In general, the patients in this study were young and relatively healthy.</td>
</tr>
<tr>
<td></td>
<td><strong>Key Exclusion Criteria:</strong></td>
<td><strong>Participant Characteristics:</strong></td>
<td>• At baseline, the median VL was 0.43 (log_{10}) c/mL lower in the NTZ arm than in the placebo arm; however, this difference was not statistically significant (trend toward a significant difference; (P = 0.065)). Although the difference in absolute VLs between the arms at Day 5 was reported as statistically significant, without the information on the change in VL in each arm, it is difficult to interpret the significance of the findings.</td>
</tr>
<tr>
<td></td>
<td>• Negative SARS-CoV-2 RT-PCR result from an NP swab</td>
<td>• Median age of patients was 37 years.</td>
<td>• Some participants who received the study drug were excluded from the analysis population due to discontinued intervention (21 in NTZ arm vs. 18 in placebo arm); AEs (6 in NTZ arm vs. 1 in placebo arm); hospitalization (5 in NTZ arm vs. 5 in placebo arm); and protocol deviations (7 in NTZ arm vs. 7 in placebo arm). This complicates the interpretation of the study results, because an ITT analysis was not included.</td>
</tr>
<tr>
<td></td>
<td>• Renal, heart, respiratory, liver, or autoimmune diseases</td>
<td>• Percentage of patients aged 18–39 years: 58%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Participant had a history of cancer in the past 5 years</td>
<td>• Percentage of patients aged 40–59 years: 36%</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Interventions:</strong></td>
<td>• Percentage of patients aged 60–77 years: 6%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• NTZ 500 mg 3 times daily for 5 days using the oral liquid formulation</td>
<td>• 53% of patients were women.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Color-matched placebo 3 times daily for 5 days</td>
<td>• 69% of patients were White.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Primary Endpoint:</strong></td>
<td>• 31% of patients had a BMI ≥30.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Complete resolution of dry cough, fever, and/or fatigue after receiving treatment for 5 days</td>
<td>• 85% of patients had no reported comorbidities.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Key Secondary Endpoints:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Reduction in SARS-CoV-2 VL</td>
<td>• Median time from symptom onset to first dose of study drug was 5 days (IQR 4–5 days).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Incidence of hospital admission after completing therapy</td>
<td>• Baseline median SARS-CoV-2 VL was 7.06 (log_{10}) c/mL (IQR 5.77–8.13) in NTZ arm and 7.49 (log_{10}) c/mL (IQR 6.15–8.32) in placebo arm ((P = 0.065)).</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Primary Outcome:</strong></td>
<td><strong>Primary Outcome:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• There was no difference in time to complete resolution of symptoms between NTZ and placebo arms ((P = 0.277))</td>
<td>• There was no difference in time to complete resolution of symptoms between NTZ and placebo arms ((P = 0.277))</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Secondary Outcomes:</strong></td>
<td><strong>Secondary Outcomes:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• After 5 days, median SARS-CoV-2 VL was lower in NTZ arm (3.63 (log_{10}) c/mL [IQR 0.00–5.03]) than in placebo arm (4.13 (log_{10}) c/mL [IQR 2.88–5.31]; (P = 0.006)).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Early Treatment of Mild COVID-19 with Nitazoxanide³, continued

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Methods</th>
<th>Results</th>
<th>Limitations and Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Treatment of Mild COVID-19 with Nitazoxanide³</td>
<td>• 29.9% of patients in NTZ arm and 18.2% of patients in placebo arm had a negative SARS-CoV-2 RT-PCR result at the fifth treatment visit ( P = 0.009 ).&lt;br&gt;• In the ITT study population, 5 patients on NTZ and 5 on placebo were hospitalized due to clinical deterioration; 2 who received NTZ required ICU admission vs. 0 who received placebo. These individuals were excluded from the analysis population because they did not complete the 5-day treatment course before clinical progression occurred.</td>
<td><strong>Interpretation:</strong>&lt;br&gt;• NTZ did not improve time to resolution of symptoms compared to placebo.&lt;br&gt;• Median VL was lower at Day 5 in the NTZ arm than in the placebo arm, but this may reflect differences in baseline VLs.&lt;br&gt;• NTZ was well tolerated.</td>
<td></td>
</tr>
</tbody>
</table>

Other Outcomes:<br>• Mild to moderate AEs occurred in about 30% of participants in each arm who completed 5 days of therapy.

### Early Treatment of Mild to Moderate COVID-19 with an Investigational Formulation of Nitazoxanide⁴

<table>
<thead>
<tr>
<th>Key Inclusion Criteria:</th>
<th>Number of Participants:</th>
<th>Key Limitations:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomized, double-blind, placebo-controlled trial in nonhospitalized patients with COVID-19 in the United States and Puerto Rico ( n = 1,092 )</td>
<td>mITT analysis: NTZ ( n = 184 ) and placebo ( n = 195 )</td>
<td>• Information is limited in this preliminary report.&lt;br&gt;• Because the number of high-risk participants who progressed to severe COVID-19 in this study was small, the results for this subgroup are fragile. Larger studies are needed.</td>
</tr>
</tbody>
</table>

This is a preliminary, unpublished report that has not been peer reviewed.

**Key Inclusion Criteria:**
• Aged \( \geq 12 \) years<br>• Enrollment \( \leq 72 \) hours of symptom onset<br>• Mild to moderate COVID-19<br>• \( \geq 2 \) respiratory symptom domains with a score \( \geq 2 \) on FLU-PRO questionnaire at screening, and no improvement in overall symptom severity compared to previous day

**Key Exclusion Criteria:**
• Signs or symptoms of severe COVID-19<br>• Previous COVID-19 or any symptom suggestive of COVID-19<br>• Recent acute upper respiratory tract infection<br>• Severe immunodeficiency<br>• Severe heart, lung, neurological, or other systemic diseases

**Participant Characteristics:**
• Median age of patients was 40 years.<br>• 43.5% of patients were men.<br>• 87.6% of patients were White.<br>• Median BMI was 28.9.<br>• Median time from symptom onset to randomization was 45.9 hours.<br>• 64.8% of patients had mild disease.<br>• 35.2% of patients had moderate disease.<br>• 62.8% of patients were at risk for severe illness.

**Primary Outcome:**
• NTZ was not associated with a reduction in median time to sustained response compared to placebo \( 13.3 \) days in NTZ arm vs. \( 12.4 \) days in placebo arm; \( P = 0.88 \)

**Secondary Outcomes:**
• Progression to severe disease occurred in 1 of 184 patients \( 0.5\% \) in NTZ arm and 7 of 195 patients \( 3.6\% \) in placebo arm \( P = 0.07 \).
Early Treatment of Mild to Moderate COVID-19 with an Investigational Formulation of Nitazoxanide⁴, continued

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Methods</th>
<th>Results</th>
<th>Limitations and Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Interventions:</strong></td>
<td><strong>Results:</strong></td>
<td><strong>Limitations and Interpretation:</strong></td>
<td></td>
</tr>
<tr>
<td>• 2 investigational NTZ 300 mg extended-release tablets (for a total dose of 600 mg) PO with food twice daily for 5 days</td>
<td>• Among a subgroup of patients who had a high risk for severe illness according to CDC criteria, 1 of 112 patients (0.9%) in NTZ arm and 7 of 126 patients (5.6%) in placebo arm progressed to severe disease ($P = 0.07$).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Matching placebo for 5 days</td>
<td>• 1 of 184 patients (0.5%) in NTZ arm and 5 of 195 (2.6%) in placebo arm were hospitalized ($P = 0.18$).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• All subjects received a vitamin B complex supplement twice daily to mask potential NTZ-associated chromaturia.</td>
<td>• There was no significant difference in viral endpoints between arms at Days 4 and 10.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Primary Endpoint:</strong></td>
<td><strong>Secondary Endpoint:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Time from first dose to sustained response</td>
<td>• Rate of progression to severe COVID-19</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other Outcomes:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• The safety analysis included 935 participants (472 in NTZ arm and 463 in placebo arm).</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• 2 patients in NTZ arm and 3 patients in placebo arm stopped the study drug due to AEs.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Key:** AE = adverse event; BMI = body mass index; CDC = Centers for Disease Control and Prevention; FLU-PRO = Influenza Patient Reported Outcomes; ICU = intensive care unit; ITT = intention-to-treat; mITT = modified intention-to-treat; NP = nasopharyngeal; NTZ = nitazoxanide; the Panel = the COVID-19 Treatment Guidelines Panel; PO = orally; RT-PCR = reverse transcription polymerase chain reaction; VL = viral load

**References**


Table 2e. Characteristics of Antiviral Agents That Are Approved or Under Evaluation for the Treatment of COVID-19

Last Updated: July 8, 2021

- The information in this table is derived from data on the use of these drugs for FDA-approved indications or in investigational trials, and it is supplemented with data on their use in patients with COVID-19, when available.
- Information on CQ, HCQ, and LPV/RTV are available in the archived versions of the Guidelines. However, the Panel recommends against using these agents to treat COVID-19.
- There are limited or no data on dose modifications for patients with organ failure or those who require extracorporeal devices. Please refer to product labels, when available.
- There are currently not enough data to determine whether certain medications can be safely coadministered with therapies for the treatment of COVID-19. When using concomitant medications with similar toxicity profiles, consider performing additional safety monitoring.
- The potential additive, antagonistic, or synergistic effects and the safety of using combination therapies for the treatment of COVID-19 are unknown. Clinicians are encouraged to report AEs to the FDA MedWatch program.
- For drug interaction information, please refer to product labels and visit the Liverpool COVID-19 Drug Interactions website.
- For the Panel’s recommendations on using the drugs listed in this table, please refer to the individual drug sections or Therapeutic Management of Hospitalized Adults With COVID-19.

<table>
<thead>
<tr>
<th><strong>Dosing Regimens</strong></th>
<th><strong>Adverse Events</strong></th>
<th><strong>Monitoring Parameters</strong></th>
<th><strong>Drug-Drug Interaction Potential</strong></th>
<th><strong>Comments and Links to Clinical Trials</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><em>The doses listed here are for approved indications or from reported experiences or clinical trials.</em></td>
<td><em>Nausea</em></td>
<td><em>Infusion reactions</em></td>
<td><em>Clinical drug-drug interaction studies of RDV have not been conducted.</em></td>
<td><em>RDV should be administered in a hospital or a health care setting that can provide a similar level of care to an inpatient hospital.</em></td>
</tr>
<tr>
<td><em>For Hospitalized Adults and Children (Aged ≥12 Years and Weighing ≥40 kg)</em></td>
<td><em>ALT and AST elevations</em></td>
<td><em>Renal function and hepatic function should be monitored before and during treatment as clinically indicated.</em></td>
<td><em>In vitro, RDV is a substrate of CYP3A4, OATP1B1, and P-gp and an inhibitor of CYP3A4, OATP1B1, OATP1B3, and MATE1.</em></td>
<td><em>RDV is approved by the FDA for the treatment of COVID-19 in hospitalized adult and pediatric patients (aged ≥12 years and weighing ≥40 kg).</em></td>
</tr>
<tr>
<td>Remdesivir</td>
<td><em>Hypersensitivity</em></td>
<td><em>Increases in prothrombin time</em></td>
<td><em>RDV is not recommended when eGFR is &lt;30 mL/min. See the Remdesivir section for a discussion on using RDV in people with renal insufficiency.</em></td>
<td><em>For the treatment of COVID-19 in hospitalized adult and pediatric patients (aged ≥12 years and weighing ≥40 kg).</em></td>
</tr>
<tr>
<td></td>
<td><em>Drug vehicle is SBECD, which has been associated with renal and liver toxicity. SBECD accumulation may occur in patients with moderate or severe renal impairment.</em></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Dosing Regimens

The doses listed here are for approved indications or from reported experiences or clinical trials.

<table>
<thead>
<tr>
<th>Remdesivir, continued</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>For Patients Who Are Not Mechanically Ventilated and/or on ECMO:</strong></td>
</tr>
<tr>
<td>• RDV 200 mg IV(^a) on Day 1, then RDV 100 mg IV on Days 2–5</td>
</tr>
<tr>
<td>• For patients who do not show clinical improvement after 5 days of therapy, treatment may be extended to up to 10 days.</td>
</tr>
<tr>
<td><strong>For Mechanically Ventilated Patients and/or Patients on ECMO:</strong></td>
</tr>
<tr>
<td>• RDV 200 mg IV(^a) on Day 1, then RDV 100 mg IV on Days 2–10</td>
</tr>
<tr>
<td><strong>Suggested Dose in EUA(^b) for Hospitalized Children</strong></td>
</tr>
<tr>
<td><strong>For Patients Weighing 3.5 kg to &lt;40 kg:</strong></td>
</tr>
<tr>
<td>• RDV 5 mg/kg IV(^a) on Day 1, then RDV 2.5 mg/kg IV once daily starting on Day 2</td>
</tr>
<tr>
<td>• For patients who are not mechanically ventilated and/or on ECMO, the duration is 5 days. If patients have not shown clinical improvement after 5 days, treatment may be extended to up to 10 days.</td>
</tr>
<tr>
<td>• For mechanically ventilated patients and/or patients on ECMO, the recommended treatment duration is 10 days.</td>
</tr>
<tr>
<td><strong>For Patients Aged &lt;12 Years and Weighing ≥40 kg:</strong></td>
</tr>
<tr>
<td>• Same dose as for adults</td>
</tr>
<tr>
<td><strong>Adverse Events</strong></td>
</tr>
<tr>
<td>• Each 100 mg vial of RDV lyophilized powder contains 3 g of SBECD, and each 100 mg/20 mL vial of RDV solution contains 6 g of SBECD.</td>
</tr>
<tr>
<td>• Clinicians may consider preferentially using the lyophilized powder formulation (which contains less SBECD) in patients with renal impairment.</td>
</tr>
<tr>
<td><strong>Monitoring Parameters</strong></td>
</tr>
<tr>
<td>• RDV may need to be discontinued if ALT level increases to &gt;10 times ULN and should be discontinued if there is an increase in ALT level and signs or symptoms of liver inflammation are observed.(^1)</td>
</tr>
<tr>
<td><strong>Drug-Drug Interaction Potential</strong></td>
</tr>
<tr>
<td>• Minimal to no reduction in RDV exposure is expected when RDV is coadministered with dexamethasone (Gilead Sciences, written communication, July 2020).</td>
</tr>
<tr>
<td>• CQ or HCQ may decrease the antiviral activity of RDV; coadministration of these drugs is not recommended.(^1)</td>
</tr>
<tr>
<td><strong>Comments and Links to Clinical Trials</strong></td>
</tr>
<tr>
<td>• An EUA(^b) is available for hospitalized pediatric patients weighing 3.5 kg to &lt;40 kg or aged &lt;12 years and weighing ≥3.5 kg.</td>
</tr>
<tr>
<td>• A list of clinical trials is available here: Remdesivir</td>
</tr>
</tbody>
</table>

\(^{1}\) Minimal to no reduction in RDV exposure is expected when RDV is coadministered with dexamethasone (Gilead Sciences, written communication, July 2020).

\(^{2}\) CQ or HCQ may decrease the antiviral activity of RDV; coadministration of these drugs is not recommended.

\(^{3}\) An EUA is available for hospitalized pediatric patients weighing 3.5 kg to <40 kg or aged <12 years and weighing ≥3.5 kg.

\(^{4}\) A list of clinical trials is available here: Remdesivir.
<table>
<thead>
<tr>
<th><strong>Dosing Regimens</strong></th>
<th><strong>Adverse Events</strong></th>
<th><strong>Monitoring Parameters</strong></th>
<th><strong>Drug-Drug Interaction Potential</strong></th>
<th><strong>Comments and Links to Clinical Trials</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><em>The doses listed here are for approved indications or from reported experiences or clinical trials.</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ivermectin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adults:</strong></td>
<td>• Generally well tolerated</td>
<td>• Monitor for potential AEs.</td>
<td>• Minor CYP3A4 substrate</td>
<td>• Generally given on an empty stomach with water; however, administering IVM with food increases its bioavailability.²</td>
</tr>
</tbody>
</table>
| • The dose most commonly used in clinical trials is IVM 0.2–0.6 mg/kg PO given as a single dose or as a once-daily dose for up to 5 days. | • Dizziness | • P-gp substrate | | • A list of clinical trials is available here: [Ivermectin](https://www.covid19treatmentguidelines.nih.gov/)
| | • Pruritis | | | |
| | • GI effects (e.g., nausea, diarrhea) | | | |
| | • Neurological AEs have been reported when IVM has been used to treat parasitic diseases, but it is not clear whether these AEs were caused by IVM or the underlying conditions. | | | |
| | • Monitor for potential AEs. | | | |
| | • Minor CYP3A4 substrate | | | |
| | • P-gp substrate | | | |
| **Nitazoxanide** | | | | |
| **Adults:** | • Generally well tolerated | • Monitor for potential AEs. | • Drug-drug interactions may occur if NTZ is administered concurrently with other highly plasma protein-bound drugs due to competition for binding sites.⁵ | • NTZ should be taken with food. |
| • Doses reported in COVID-19 studies range from NTZ 500 mg PO 3 times daily to 4 times daily.²⁴ Higher doses are being studied ([ClinicalTrials.gov Identifier](https://clinicaltrials.gov/ct2/) NCT04746183). | • Abdominal pain | | | • The oral suspension is not bioequivalent to the tablet formulation. |
| | • Diarrhea | | | | • A list of clinical trials is available here: [Nitazoxanide](https://www.covid19treatmentguidelines.nih.gov/) |
| | • Headache | | | |
| | • Nausea | | | |
| | • Vomiting | | | |
| | • Urine discoloration | | | |
| | • Ocular discoloration (rare) | | | |
| | • Monitor for potential AEs. | | | |
| | • Minor CYP3A4 substrate | | | |
| | • P-gp substrate | | | |

² Infuse over 30–120 minutes.

⁴ The FDA EUA permits the emergency use of RDV for the treatment of suspected COVID-19 or laboratory-confirmed SARS-CoV-2 infection in hospitalized pediatric patients weighing 3.5 kg to <40 kg or aged <12 years and weighing ≥3.5 kg.⁵
Key: AE = adverse event; ALT = alanine transaminase; AST = aspartate aminotransferase; CQ = chloroquine; CYP = cytochrome P450; ECMO = extracorporeal membrane oxygenation; eGFR = estimated glomerular filtration rate; EUA = Emergency Use Authorization; FDA = Food and Drug Administration; GI = gastrointestinal; HCQ = hydroxychloroquine; IV = intravenous; IVM = ivermectin; LPV/RTV = lopinavir/ritonavir; MATE = multidrug and toxin extrusion protein; NTZ = nitazoxanide; OATP = organic anion transporter polypeptide; the Panel = the COVID-19 Treatment Guidelines Panel; P-gp = P-glycoprotein; PO = orally; RDV = remdesivir; SBEC = sulfobutylether-beta-cyclodextrin; ULN = upper limit of normal

References


